龙丰低估值叠加高股息 价值显现

香港, 2026年6月8日 - (亚太商讯 via SeaPRwire.com) - 龙丰集团(2290)刚于周五挂牌上市,公开发售超过660倍。按周五收市价计,市值约14.05亿港元,公司预估2026财年纯利约2.65亿港元,即2026年预测市盈率只有5.3倍,大幅低于同业如DFI零售集团(22.2倍)、莎莎国际(26.8倍)及国际家居零售(12倍),反映其估值远低于同业水平,存在较大的重估空间,对投资者而言具备良好的配置价值。此外,龙丰上市后预期每年派息不少于可分配溢利的50%,按现价计算股息率约达9.4%,远超同业普遍的3%至6%及行业平均4%水平。当前同业估值偏高且回报有限,龙丰却能同时提供低估值与高股息,性价比优势不言而喻。基本面稳固加上全渠道发力,后市可为投资最重要的是看公司的前景及基本面。龙丰现有31间分店,主打“一站式”购物体验,吸引大量本地消费者及游客。公司计划未来三个财年新增18至21间门店,考虑到其新店平均仅需3个月内即达至收支平衡,2至8个月内回本,足见其营运效率与盈利能力在行业中具备无可比拟的竞争优势。此外,龙丰单店可售SKU超过9,000个,涵盖美容护肤、保健品、医药、母婴等11个核心品类,惟公司并未止步,持续拓展商品组合和种类,并深化自家品牌发展。自家品牌具备较高毛利及差异化优势,有助进一步提升品牌价值与盈利能力。除线下扩张外,龙丰同步推进线上渠道建设,实现线上线下协同发展。公司计划通过目前合作的天猫、京东等主流电商平台加强销售,同时积极布局抖音等新兴社交电商渠道,通过内容营销触达更广泛的中国内地消费群体,持续完善线上销售网络。尽管目前线上业务占比仍然较低,但随着消费模式转变,相关渠道具备较大成长空间。公司亦计划持续优化会员体系及强化数据分析能力,以提升转化率及用户黏性,同时推动线上与线下库存及销售协同,提升整体营运效率。随着全渠道策略逐步深化,龙丰有望在拓阔收入来源的同时,提升经营灵活性与资源配置效率,为未来业绩提供持续支撑。供应链垂直延伸,盈利质量持续提升龙丰已建立覆盖全球的采购体系,与超过600家供货商保持合作,来源涵盖日本、韩国及欧美市场,为产品多样性及成本竞争力提供稳固支撑。公司更计划透过策略投资及并购延伸至上游供货商及OEM制造端,全面提升供应链掌控力。随着中间环节减少及规模效应释放,成本控制能力持续改善,毛利率已由2023财年的约24.9%提升至2025财年的约31.6%。随着未来逐步参与上游环节,公司在产品定价、产品开发及供应节奏上将具备更高灵活性,亦有助支持自有品牌发展,进一步提升盈利质量。对市场而言,这类由零售端向上游供应链延伸的模式升级,往往为估值提供重新定价的契机。龙丰集低估值及高股息于一身。在业绩持续增长的同时,供应链延伸、门店扩张及全渠道发展等发展策略清晰落地,为未来提供多重支撑,而稳定派息政策则构建可靠的现金回报基础。相比同业动辄20倍以上市盈率水平,龙丰在估值与回报两方面均具明显优势。在估值尚未充分反映其盈利质素及成长潜力的情况下,随着业绩兑现、规模效应释放及业务结构优化逐步体现,市场对其盈利质素的认知有望提升。对于同时关注增长与收益的投资者而言,龙丰的价值正逐步显现。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More

C.banner to Acquire Controlling Stake in Benyuan Zhishu to Establish Dual-core Businesses: Footwear + AI Data

HONG KONG, Jun 8, 2026 - (ACN Newswire via SeaPRwire.com) - C.banner International Holdings Limited (Stock Code: 1028.HK, hereinafter referred to as "C.banner" or the "Group") announced that it has signed an investment agreement with Benyuan Zhishu, a leading domestic AI data service provider, and its shareholders: The Group will acquire controlling equity in Benyuan Zhishu through existing equity purchase and new share subscription, incorporating it into the Group's consolidated financial statements after the transaction is completed. With this, C.banner has formally established a dual-core business framework of "Footwear + Artificial Intelligence Data" while maintaining stable operations in its footwear business.This is a strategic layout that integrates an AI data business that has demonstrated profitability and has been validated by top-tier customers over the long term—its growth is based on real revenue and profit.I.Rationale for Data: The Competition in AI is Shifting from "Computing Power" to "Experience"The competition in artificial intelligence is undergoing a foundational shift. Over the past decade, outcomes were mainly determined by computing power and model architecture; however, as public data is gradually absorbed by large models and computing power and algorithms become increasingly common, the next critical bottleneck is no longer "whose model is bigger," but "who can continuously provide models with new, more complex, real-world high-quality experiences."This is precisely the rare and critical value of this field: computing power can be purchased, algorithms can be replicated, but scaling and verifying the transformation of expert human judgments and real-world physical interaction feedback into model-trainable data is challenging, slow, and not easily expedited by capital—making it the truly essential step in the industry. The industry has identified 2026 as the "Year of Data Scaling" for embodied intelligence, and the market is repricing accordingly: In 2025, Meta invested approximately $14.3 billion, corresponding to a valuation of around $29 billion, in data annotation company Scale AI, reflecting a shift in the perception of AI data from a "cost item" to a "strategic asset."II.Rationale for Benyuan Zhishu: Positioned at the Most Critical and Irreplaceable Step in the Value ChainBenyuan Zhishu, established in 2015, operates upstream in the artificial intelligence value chain, focusing on converting human expert knowledge and experience into high-quality, trainable and verifiable data for AI models. In contrast to low-barrier general annotation services, it specializes in data services with high technological difficulty and strict professional requirements. It has grown into one of the few domestic providers capable of delivering comprehensive data services for large models, world models, and embodied intelligence, occupying a scarce position in the "Physical AI" wave.Its competitive advantage has been forged through long-term validation by the most demanding customers and the most challenging tasks. Benyuan Zhishu serves leading domestic large model infrastructure providers, top-tier internet platforms, frontline game publishers, and leading embodied intelligence companies, undertaking high-difficulty, quality-demanding data tasks—organizing professionals in fields such as mathematics, coding, law, and medicine to perform expert-level annotations, building evaluation datasets to measure the true capabilities of models, reconstructing virtual environment data for world models, and collecting real-world physical interaction data for embodied intelligence. These collaborations require stringent entry barriers, long-term adaptation, and continuous quality validation. Benyuan Zhishu has become the exclusive data supplier for several high-value data categories for related clients, demonstrating strong customer loyalty and sustainability. With nationwide delivery centers, a crowdsourced network of hundreds of thousands of domain experts, and proprietary data platforms, Benyuan Zhishu is capable of large-scale delivery under high information security standards.It is also a profitable AI company. For the fiscal years ending December 31, 2024 and 2025, Benyuan Zhishu achieved revenues of approximately RMB 146.5 million and RMB 156.2 million, respectively, with post-tax net profits of approximately RMB 7.1 million and RMB 11.1 million. According to its latest management accounts, its revenue for the first five months of 2026 has seen strong growth. In an AI environment heavily reliant on external financing, a data company built on real orders and revenue growth, and already profitable, is distinctive.III.Rationale Behind the Structure: Stable Investment, Dual Engines, and Preserved NeutralityThe transaction structure balances the interests of the buyer, seller, and customers.Stable investment: The transaction is financed using internal Group resources. The footwear business of C.banner continues to generate stable operating cash flows and maintain a net cash position, providing a financial foundation for the growing AI data business without relying on large-scale external financing.Growth-focused Capital Allocation: The share subscription consideration in this transaction will be used to expand Benyuan Zhishu’s production capacity and technology development; simultaneously, the founding team will retain partial equity to align their interests with the Group.Preserved Operational Neutrality: Upon transaction completion, Benyuan Zhishu will retain its independent brand and operate independently, implementing data isolation mechanisms. Since C.banner itself does not engage in AI model development nor compete with Benyuan Zhishu’s customers, industry competitors of Benyuan Zhishu’s clients can continue collaborating with the same neutral supplier with confidence. For a data company, a capital structure that does not compromise neutrality is especially crucial. Moreover, Benyuan Zhishu's data and data governance capabilities can also be applied to the Group's footwear retail supply chain, design, and marketing segments, enhancing the operational efficiency of the traditional core business through artificial intelligence.IV.Management StatementThe management of C.banner stated: “We believe that high-quality data is one of the most critical and scarce infrastructures in the era of artificial intelligence. This transaction allows the Group to enter this rapidly growing sector while maintaining a stable foundation in the consumer industry. We look forward to working with Benyuan Zhishu to continuously provide 'data fuel' of high quality to China's AI industry, creating sustainable long-term value for our shareholders under the dual-core business framework.”Benyuan Zhishu’s founder and CEO, Li Niyong, will also issue a public letter on the same day to share the company’s vision and the significance of this cooperation. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
HKTDC’s ‘Hong Kong Tech Pavilion’ at Paris VivaTech 2026 to showcase 24 Hong Kong startups to connect global investment opportunities ACN Newswire

HKTDC’s ‘Hong Kong Tech Pavilion’ at Paris VivaTech 2026 to showcase 24 Hong Kong startups to connect global investment opportunities

HONG KONG, Jun 7, 2026 - (ACN Newswire via SeaPRwire.com) - The Hong Kong Trade Development Council (HKTDC) will host a "Hong Kong Tech Pavilion" at Viva Technology (VivaTech) 2026, Europe’s premier annual startup and technology summit in Paris, from next Wednesday, 17 to Saturday, 20 June. In collaboration with our strategic partner, the Hong Kong Economic and Trade Office in Brussels, the Pavilion will bring together 24 Hong Kong startups to showcase innovations in artificial intelligence and robotics, health technology, and sustainability and climate technology. A series of thematic seminars, startup pitching sessions, and networking receptions will also be held to facilitate exchanges between global investors, buyers, and Hong Kong startups, fostering international collaboration. Several key partners, including Hong Kong Science and Technology Parks Corporation, Hong Kong Polytechnic University, Hong Kong Productivity Council, Hong Kong University of Science and Technology, and Cyberport, support the initiative.HKTDC’s Chris Lo, Regional Director, Europe, Central Asia & Israel, stated: "Hong Kong is actively developing into an international innovation and technology hub. As one of the key enablers, the HKTDC supports enterprises in going global by curating overseas platforms and facilitating cross-regional exchanges. Building on last year's success, we are further expanding the Hong Kong Tech Pavilion at VivaTech this year to deepen connections among startups, tech leaders, large corporations, and investors, fostering innovative collaborations and business matchmaking, assisting innovation and technology enterprises in exploring overseas markets, and showcasing to Europe Hong Kong's unique advantages as an international innovation hub."During the exhibition, the HKTDC will organise a series of events, including thematic seminars, startup pitching sessions, and networking activities, to explore future development trends for Hong Kong startups and global collaboration opportunities.Shirley Yung, Special Representative for Hong Kong Economic & Trade Affairs to the European Union, will attend and deliver a keynote speech at the thematic seminar and networking reception titled "Building Resilient Tech Ecosystems: Powering the Next Wave of International Tech Leadership from Hong Kong" on 19 June. The seminar will feature three main segments: "Launching from Hong Kong: The Innovation Infrastructure Powering Start-up Breakthrough”, where Hong Kong Science and Technology Parks Corporation, and startups will share local success stories; "Engineering for Success: How Hong Kong’s Innovation Landscape Helps Tech Companies Achieve Market Fit'”, featuring Hong Kong Productivity Council and enterprise representatives exploring market matchmaking; and a concluding panel discussion inviting representatives from academia, incubators and technology institutions to examine how talent and infrastructure drive Hong Kong's technological development and international collaboration.Helping Hong Kong startups pitch to global investorsParticipating startups at VivaTech’s Hong Kong Tech Pavilion will showcase their innovative solutions and products to investors from around the world. Three thematic pitching sessions will be held over the first three days:17 June (afternoon): Robotics and Microelectronics theme, featuring seven enterprises showcasing their innovative achievements including Bacbudy Limited, which develops intelligent wearable and robotic assistive devices for the lower back, and Cybercrystal Technology Co., which researches next-generation robotic optical tactile skin.18 June (morning): Artificial Intelligence and Health Technology theme, featuring eight enterprises presenting breakthrough innovations in AI and health technology including Eieling Technology, which develops portable chronic liver disease medical diagnostics and AI applications, and Point Fit Technology, which develops wearable health monitoring and intelligent sports solutions.19 June (noon): Sustainability and Climate Technology theme, featuring seven enterprises including Albacastor Technology, which develops eco-friendly industrial oil-removal and deodorising ventilation systems, and Green Vigor, which develops energy recovery and green power generation technologies.Additional events include: On the first day (17 June), the thematic seminar "Europe to Hong Kong: Building a Startup Between Two Ecosystems" will be moderated by Christopher Lai, Director, France, Spain & Portugal of HKTDC, inviting French entrepreneurs to share their experiences in business expansion across Europe and Hong Kong, analysing the differences between the two ecosystems, and exploring how to leverage Hong Kong as a platform for entering the Asian market and securing funding.On the exhibition’s second day (18 June), Hong Kong Science and Technology Parks Corporation will host the "HKSTP Global Mixer: Inside Hong Kong’s Startup Acceleration Playbook", exploring how Hong Kong connects with the global innovation and technology ecosystem and its advantages in talent and investment. In the same afternoon, Hong Kong Polytechnic University will host the “Breaking Barriers with Autonomous Systems: Transforming Industries with AI Innovation”, showcasing Hong Kong’s unique position in harnessing the power of AI and its world-class academia to develop a globally leading innovation hub. That evening, the "Hong Kong Tech Night: Where Innovation Meets Opportunity" networking event will bring together the innovation and technology communities of Hong Kong and France, fostering collaboration between both sides in talent, funding, and market expansion.The VivaTech 2026 Hong Kong Tech Pavilion is located at Booth 1C11, Hall 7.1, Paris Expo Porte de Versailles. The 10th edition of VivaTech is expected to attract more than 180,000 visitors, 14,000 global startups, and 3,600 investors, bringing together industry leaders from around the world to become a key focal point of the international innovation and technology ecosystem.VivaTech Hong Kong Tech Pavilion is an Economic and Trade Express flagship event, which helps Hong Kong SMEs and startups explore overseas market opportunities while attracting more companies to invest and establish operations in Hong Kong.List of 24 Start-ups at the Hong Kong Tech Pavilion: CategoryCompany Name1. Sustainable & Climate TechnologyAlbacastor Technology Limited2. AIGreen Limited 3. Asgard Group Limited 4. Formwork IO5. Green Vigor Limited6. Laputa Eco-Construction Material Company Limited7. LeafIoT Technology Limited8. Plasticvore Chain Ltd 9. AI and Software Solutions Cogniser Infotech Ltd10. D-Engraver Limited11. Midas Analytics Limited 12. OxGen Holdings Limited13. Pantheon Lab Limited14. SagaDigits Limited15. Robotics and Microelectronics TechnologyAnlaseo Technology Limited16. Bacbudy Limited17. Cybercrystal Technology Co., Limited18. Harmony SkyTech Limited19. Oriental Materials Hong Kong Limited20. Robocore Technology Limited21. Health TechnologyEieling Technology Limited22. Hong Kong Bionic Beet Robotics Limited23. Point Fit Technology Limited 24. UniversityThe Hong Kong Polytechnic UniversityPhoto download: https://bit.ly/3RxuMDZThe HKTDC will host the Hong Kong Tech Pavilion at VivaTech 2026. The picture shows last year’s pavilion. During VivaTech, the HKTDC will host a series of exciting events including thematic seminars, startup pitching sessions, and networking receptions, and will arrange business matchmaking with representatives from various enterprises and organisations to assist startups in exploring the European market.Websites: https://vivatech.com/exhibitors/hktdc-hong-kong-trade-development-councilMedia enquiriesFor enquiries, please contact HKTDC’s Communications & Public Affairs Department:Winnie KanTel: (852) 2584 4055Email: winnie.wy.kan@hktdc.orgMedia Room: http://mediaroom.hktdc.comAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) celebrates its 60th anniversary this year. The HKTDC is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
iHerb Expands Consumer Benefits Across Asia with 618 Shopping Festival ACN Newswire

iHerb Expands Consumer Benefits Across Asia with 618 Shopping Festival

IRVINE, CA, June 7, 2026 - (ACN Newswire via SeaPRwire.com) - iHerb, a global e‑commerce platform specializing in health and wellness products, has officially launched its 2026 “618 Peak Shopping Festival.” As a brand with a 29‑year heritage, this initiative brings a range of promotional offers and localized services to customers in Hong Kong and Southeast Asia, reflecting the company’s ongoing commitment to enhancing accessibility and customer experience across international markets.Founded in 1996, iHerb has expanded its operations to 185 countries and regions and now serves more than 11 million active users worldwide. Through its direct sourcing model and global fulfillment network, the company has focused on providing consumers with access to a broad range of international health, wellness, beauty, and personal care products.Unlike traditional cross-border retail models that often involve multiple intermediaries, iHerb purchases products directly from manufacturers and distributes them through its own warehouse network. The company stated that this approach helps improve supply chain transparency and product traceability while streamlining international delivery.As part of the 618 campaign, iHerb highlighted a selection of products from popular categories frequently purchased by consumers, including dietary supplements, personal care products, sports nutrition items, and beauty products.Among the featured products are:California Gold Nutrition LactoBif(R) 30 Billion Probiotics (CGN00965), a probiotic supplement packaged in individually sealed blister packs for convenient storage and transportation.Doctor's Best High Absorption Magnesium (DRB00087), a magnesium supplement formulated using Albion(R) TRAACS(R) chelation technology.Nature's Way Alive! Hair, Skin and Nails Gummies (NWY11534), a strawberry-flavored gummy supplement containing vitamins, collagen, and other nutritional ingredients.Metagenics OmegaGenics(R) Fish Oil EPA-DHA (MTG93873), a fish oil supplement containing EPA, DHA, and omega-3 fatty acids.ProHealth Longevity NMN Pro 1000 (PHV77904), an NMN supplement designed for adult consumers interested in wellness-focused nutritional products.The company noted that these products represent some of the diverse categories available on the platform, which currently offers nearly 3,000 brands and more than 50,000 products globally.To commemorate its 29th anniversary and the 618 Shopping Festival, iHerb announced several promotional initiatives for customers in Hong Kong and Southeast Asia:New customers can use the code WELCOME7 to receive a first-order discount.From June 11 to June 20, customers can use 618SALE26 for sitewide promotional savings.Additional regional promotions are available through the end of June using code 6HK75, subject to applicable terms and conditions.Customers in Hong Kong may qualify for free shipping on eligible orders and access local express delivery options.In addition to promotional activities, iHerb continues to expand localized services across Asian markets. Customers can shop through the company's website and mobile application, with support for local currencies and multiple payment methods, including credit cards and digital wallets.As iHerb marks its 29th anniversary, the company stated that it will continue investing in supply chain infrastructure, customer service, and regional fulfillment capabilities to support consumers seeking access to international health and wellness products.Company: iHerb, LLCContact Person: Kelly ChaiEmail: china.sm@iherb.com Website: iherb.com Telephone: (1) 951 6163600 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
Central Asia visit drives multi-sector collaboration, Business delegation signed 66 MoUs and agreements to seize Belt and Road opportunities ACN Newswire

Central Asia visit drives multi-sector collaboration, Business delegation signed 66 MoUs and agreements to seize Belt and Road opportunities

Tashkent, Uzbekistan, Jun 5, 2026 - (ACN Newswire via SeaPRwire.com) - A business delegation led by the Chief Executive of the Hong Kong Special Administrative Region (HKSAR), John Lee, and organised by the Hong Kong Trade Development Council (HKTDC), completed its first stop in Kazakhstan from 1 to 3 June and are now visiting Tashkent, the capital of Uzbekistan, for the final leg of its Central Asia tour from 4 to 5 June. During the visit, the delegation met with senior representatives of the local government and business communities, successfully advancing collaboration opportunities across multiple sectors.The HKTDC will follow up on key projects facilitated during the visit by providing professional post-‘mission business matching and support services, with a view to expediting project implementation while continuing to assist Hong Kong enterprises in exploring further international cooperation opportunities.The business delegation facilitated the signing of 66 memoranda of understanding (MoUs) and agreements during its visit to Kazakhstan and Uzbekistan, covering areas such as trade, investment, finance, technology and aviation. In addition, 15 cooperation agreements were signed at the government level, while non-delegation members signed 15 MoUs in areas including academia and culture, bringing the total number of agreements and MoUs signed to 96. These outcomes have laid a solid foundation for deepening economic and trade ties among Hong Kong, the Chinese Mainland, Kazakhstan and Uzbekistan, underscoring Hong Kong’s role as a key platform for Mainland enterprises to go global and further promoting long-term collaboration with Central Asian markets. Looking ahead, the parties look forward to welcoming more Central Asian enterprises to Hong Kong and HKTDC’s flagship international conferences and exhibitions, including the Belt and Road Summit and InnoEX, to capitalise on Hong Kong’s strengths as an international business and trading hub and further deepen cooperation.During its stay in Uzbekistan, the delegation met with senior officials, trade bodies and business representatives, including the Ministry of Investment, Industry and Trade (MIIT) of Uzbekistan and Uzbekistan Chamber of Commerce, and IT Park Uzbekistan, to gain in-depth insights into the country’s economic developments, market environment and investment opportunities.Summing up the Central Asia visit, Mr Lee said: “The purpose of this visit is threefold. First, to further explore emerging markets and lay a solid foundation for long-term economic and trade development. Second, to strengthen government-to-government relations and promote closer bilateral cooperation. Third, to establish a hub-to-hub cooperation model.During the visit, I led a delegation of 75 business leaders from Hong Kong and Mainland enterprises to Kazakhstan and Uzbekistan — the two largest economies among the five Central Asian countries. The delegation attended more than 20 events and inspected multiple projects in the finance, innovation and technology, and infrastructure sectors. The visit was highly successful and achieved eight major outcomes.”Mr Lee held meetings with the Presidents, Prime Ministers and other senior officials of the two countries. Both sides agreed to strengthen high-level communication and pursue multi-faceted collaboration. The Government of Uzbekistan has agreed to establish a Consulate General in Hong Kong. In addition, multiple agreements were signed, including projects with substantial investment value.Both sides recognised that the hub-to-hub cooperation model will create broader and deeper collaboration between the two regions and drive high-quality development. They will increase high-level mutual visits, support each other’s promotional activities and jointly expand their networks.”To deepen economic and trade cooperation, the HKSAR Government and the HKTDC jointly hosted a business dinner in Uzbekistan, attracting around 230 business leaders and senior officials. Prof Frederick Ma, Chairman of the HKTDC, said at the dinner: “The Central Asia visit has delivered fruitful outcomes and once again reaffirmed the trust placed by Central Asian countries in Hong Kong’s role as a bridge. In tapping emerging markets, such as Kazakhstan and Uzbekistan, Hong Kong, with its international credibility, robust institutional framework, world-class professional services and the HKTDC’s global network, serves not only as a key springboard for Mainland enterprises to go global, but also as a gateway for overseas enterprises to enter the Mainland market, effectively facilitating two-way investment and trade flows. This virtuous cycle of going global and attracting foreign investment fully demonstrates Hong Kong’s irreplaceable value under the Belt and Road Initiative as well as the HKTDC’s strengths as the preferred platform for enterprises pursuing two-way expansion.”The delegation comprised business leaders from Hong Kong and 17 provinces and municipalities across the Chinese Mainland, spanning a broad range of sectors, including financial and professional services, logistics and transportation, innovation and technology, trade, green industries as well as the media. For the first time, representatives from journalism associations joined the delegation, in response to the Policy Address’s initiative to assist the local media in expanding their network beyond Hong Kong and telling the good stories of Hong Kong. During its Kazakhstan visit, the delegation facilitated 43 MoUs and agreements, including:1.Hong Kong Trade Development Council (HKTDC) and National Chamber of Entrepreneurs of the Republic of Kazakhstan "Atameken"2.Hong Kong Trade Development Council (HKTDC) and Astana International Financial Centre (AIFC)3.Hong Kong Trade Development Council (HKTDC) and Satbayev University4.Airport Authority Hong Kong and Almaty International Airport5.Belt and Road General Chamber of Commerce and National Chamber of Entrepreneurs of the Republic of Kazakhstan "Atameken"6.Belt and Road General Chamber of Commerce and Commex HK Link Digital Trading Company Limited and Eurasian Trading System Export” International Commodity Exchange (ETSE)7.Belt and Road General Chamber of Commerce and JINGSH CONSULTING LLP8.Chinese Manufacturers Association and National Chamber of Entrepreneurs of the Republic of Kazakhstan "Atameken"9.Cyberport and Astana Hub10.Federation of Hong Kong Industries (FHKI) and Ministry of Artificial Intelligence and Digital Development in Kazakhstan11.Hong Kong Exchange and Clearing Limited and Astana International Exchange (AIX)12.Hong Kong Exchange and Clearing Limited and Astana International Financial Centre (AIFC)13.Hong Kong Science and Technology Parks and Astana Hub14.Hong Kong-Shenzhen Innovation and Technology Park Ltd. and Astana Hub15.The Hong Kong General Chamber of Commerce and National Chamber of Entrepreneurs of the Republic of Kazakhstan "Atameken"16.Law Society of Hong Kong and National Bar Association of Kazakhstan17.BOCHK and Bank of China Kazakhstan and Baiterek18.BOCHK and Samruk Kazyna19.Bosera International Asset Management Limited and JSC "Halyk Bank of Kazakhstan"20.Cathay Pacific and Almaty International Airport and Almaty City Government (Tourism Development)21.China International Capital Corporation Limited and Freedom Holdings22.China International Capital Corporation Limited and Samruk Kazyna23.China International Capital Corporation Limited and Astana International Financial Centre (AIFC)24.China International Capital Corporation Limited and Air Astana25.Deloitte China and Universal Energy Co., Ltd.26.Ewpartners Investment Management Limited and Dasco Capital Ltd.27.Ewpartners Investment Management Limited and Astana International Financial Centre (AIFC)28.Ewpartners Investment Management Limited and Jiangsu Solicitude Medical Technology (Group) Limited and Samruk-Kazyna Invest LLP29.Goldford Group and Gas Energy Solution LLP30.Hong Kong News Executives’ Association and The Newspaper Society of Hong Kong and Khabar Agency JSC31.Jardine Matheson and KIDF32.Jiaxin International Resources Investment Limited and Industry and Construction of the Republic of Kazakhstan33.Koln 3D Technology (Medical) Limited and Kazakh Research Institute of Oncology and Radiology34.PCCW Limited and Kazakhtelecom35.PCCW Limited and Khabar Agency JSC36.SCMP and Astana International Financial Centre (AIFC)37.SCMP and GOBI PARTNERS and Astana Hub and Khan Tengri Innovation Hub38.Soy-Sky FarmTech Company Limited (Hong Kong) and JSC NC Food Contract Corporation of Kazakhstan39.Standard Chartered Bank and Development Bank of Kazakhstan40.Standard Chartered Bank and Hangzhou CIEC Group Co., Ltd.41.Templewater Limited and Freedom Holdings42.The Standard and Freedom Horizons43.Walvax Biotechnology Co., Ltd. and Gold Astrum LLC During its Uzbekistan visit, the delegation facilitated 23 MoUs and agreements, including:1.Hong Kong Trade Development Council (HKTDC) and Chamber of Commerce and Industry of Uzbekistan (CCIU)2.Hong Kong Trade Development Council (HKTDC) and IT Park Uzbekistan3.Airport Authority Hong Kong and Fly Khiva Group4.Belt and Road General Chamber of Commerce and Commex HK Link Digital Trading Company Limited and SINOCHEM PLASTICS GROUP “MCHJ XK”5.Belt and Road General Chamber of Commerce and Chamber of Commerce and Industry of Uzbekistan (CCIU)6.Belt and Road General Chamber of Commerce and JINGSH CONSULTING LLP7.Chinese Manufacturers' Association of Hong Kong and Chamber of Commerce and Industry of Uzbekistan (CCIU)8.Federation of Hong Kong Industries (FHKI) and Tashkent City Municipality9.Cyberport and IT Park Uzbekistan10.The Hong Kong General Chamber of Commerce and Chamber of Commerce and Industry of Uzbekistan (CCIU)11.Law Society of Hong Kong and Chamber of Advocates of the Republic of Uzbekistan12.A-Grade Energy Ltd and Zarafshan Golden Group of Uzbekistan13.China International Capital Corporation Limited and National Bank of Uzbekistan14.China International Capital Corporation Limited and Tashkent City Municipality of the Republic of Uzbekistan15.Deloitte China and Orient Group and CITIC16.Goldford Group and Automated Solutions Center17.Templewater Limited and Uzbek-Oman Investment Company LLC18.Templewater Limited and CSCEC INTERNATIONAL MCHJXK (China State Construction International Holdings Limited)19.Templewater Limited and Tashkent City Municipality of the Republic of Uzbekistan20.The Standard and Tashkent City Municipality of the Republic of Uzbekistan21.Changchun GeneScience Pharmaceutical Co., Ltd. with Vita Group Farm22.Guangzhou Pharmaceutical Holdings Limited and ADN Pharm-Sanoat Uzbekistan23.Shaanxi Tirain Science & Technology Co., Ltd. and Geodesy, Cartography and Remote Sensing Department, Cadastral Agency under the State Tax Committee of the Republic of UzbekistanOther non-delegate organisations have also taken this opportunity to establish collaborations in various fields, including education, culture, and more:1.A-Grade Energy Ltd and Ministry of Artificial Intelligence and Digital Development of the Republic of Kazakhstan2.A-Grade Energy Ltd and Freedom Holdings3.China Mobile International Limited and Qazpost-YTO4.City University of Hong Kong and JSC "Center for International Programs under the Ministry of Science and Higher Education of the Republic of Kazakhstan5.City University of Hong Kong and Satbayev University6.City University of Hong Kong and Tashkent State Technical University7.Education University of Hong Kong and Nazarbayev University8.HKT and Education University of Hong Kong9.Hong Kong Polytechnic University and Nazarbayev University10.Hong Kong Polytechnic University and El-Yurt Umidi Foundation11.Hong Kong Polytechnic University and New Uzbekistan University (NUU)12.Thei and BILIM-INNOVATION International Social Foundation13.Thei and L.N. Gumilyov Eurasian National University14.CCBI and Uzbekistan BA Association15.West Kowloon Cultural District Authority – Hong Kong Palace Museum and State Museum of History of UzbekistanPhoto download: https://bit.ly/4fmUpRLSumming up the Central Asia visit, John Lee, Chief Executive of the HKSAR, said: “The purpose of this visit is threefold. First, to further explore emerging markets and lay a solid foundation for long-term economic and trade development. Second, to strengthen government-to-government relations and promote closer bilateral cooperation. Third, to establish a hub-to-hub cooperation model.During the visit, I led a delegation of 75 business leaders from Hong Kong and Mainland enterprises to Kazakhstan and Uzbekistan — the two largest economies among the five Central Asian countries. The delegation attended more than 20 events and inspected multiple projects in the finance, innovation and technology, and infrastructure sectors. The visit was highly successful and achieved eight major outcomes.”Prof Frederick Ma, Chairman of the HKTDC, joined John Lee, Chief Executive of the HKSAR, senior officials of the HKSAR Government and members of the delegation in meeting the media, noting that the Central Asia visit led by the Chief Executive has successfully opened doors to business cooperation with Central AsiaThe HKSAR Government and the Hong Kong Trade Development Council (HKTDC) jointly hosted a business dinner in Uzbekistan, attracting around 230 business leaders and senior officialsProf Frederick Ma, Chairman of the HKTDC, said at the dinner: “The Central Asia visit has delivered fruitful outcomes and once again reaffirmed the trust placed by Central Asian countries in Hong Kong’s role as a bridge. In tapping emerging markets, such as Kazakhstan and Uzbekistan, Hong Kong, with its international credibility, robust institutional framework, world-class professional services and the HKTDC’s global network, serves not only as a key springboard for Mainland enterprises to go global, but also as a gateway for overseas enterprises to enter the Mainland market, effectively facilitating two-way investment and trade flows. This virtuous cycle of going global and attracting foreign investment fully demonstrates Hong Kong’s irreplaceable value under the Belt and Road Initiative as well as the HKTDC’s strengths as the preferred platform for enterprises pursuing two-way expansion.”During its visit to Uzbekistan, the delegation facilitated 23 memoranda of understanding (MoUs) and agreementsThe delegation met with representatives of the Ministry of Investment, Industry and Trade (MIIT) of Uzbekistan to gain in-depth insights into bilateral trade and investment opportunities. During the meeting, Prof Frederick Ma, Chairman of the HKTDC, met with Khodjayev Jamshid Abdukhakimovich, Deputy Prime Minister of the Republic of UzbekistanThe delegation met with representatives of the Uzbekistan Chamber of Commerce to gain in-depth insights into the country’s economic developments, market environment and investment opportunitiesThe delegation visited IT Park Uzbekistan to learn about the latest developments in innovation and technologyMedia enquiriesHKTDC’s Communications & Public Affairs Department:Johnny Tsui Tel: (852) 2584 4395 Email: johnny.cy.tsui@hktdc.orgSerena Cheung Tel: (852) 2584 4272 Email: serena.hm.cheung@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) celebrates its 60th anniversary this year. The HKTDC is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More

云英谷科技登陆港交所主板 内地OLED显示驱动芯片领军企业登陆国际资本市场

香港, 2026年6月5日 - (亚太商讯 via SeaPRwire.com) - 全球显示驱动芯片市场正经历深刻变革。AMOLED 凭借轻薄、低功耗、高对比度及可弯曲等特性,正加速取代传统 LCD,成为智能手机、可穿戴设备及 VR/AR 头戴装置的主流显示方案。随着 AMOLED 渗透率持续攀升,上游显示驱动芯片的战略地位愈发关键。2026 年 5 月 27 日,云英谷科技股份有限公司(「云英谷科技」或「公司」,股份代号:3310)正式登陆香港联交所主板,作为内地 OLED 显示驱动芯片领军企业登陆国际资本市场。本次上市全球发售获市场高度认可,香港公开发售录得 3559.68 倍超额认购,国际配售获 7.05 倍超额认购,最终发行价定为每股 20.81 港元;上市首日股价表现强劲,收报 39.9 港元,较发行价上涨 91.7%,全日成交 1681.27 万股,总成交金额 5.35 亿港元,资本市场反应热烈。AMOLED 芯片国产替代的领跑力量云英谷科技于 2012 年成立,是一家专注于 AMOLED 显示驱动芯片及 Micro-OLED 显示背板驱动的 Fabless 设计公司。根据弗若斯特沙利文报告,按 2024 年销量计,公司为全球智能手机 AMOLED 显示驱动芯片第五大供应商、中国大陆最大供应商;在中国大陆市场销量排名第三,市场份额达 12.4%,居本土供应商首位。在 Micro-OLED 显示背板驱动领域,公司全球排名第二,市场份额高达 40.7%,仅次于日本索尼,在两大高增长显示技术赛道均稳居头部梯队。AMOLED 显示驱动芯片前装品牌市场认证门槛极高,云英谷科技是中国大陆首家通过品牌客户认证、唯一累计出货超千万颗的企业。截至 2024 年底,产品已应用于全球多个头部智能手机品牌的超 10 个产品系列,多为独家或核心供应商,客户黏性与先发优势突出。在 VR/AR 核心元件 Micro-OLED 显示背板驱动领域,公司为全球先行者,2024 年全球市占率超四成。随着 AI 可穿戴需求爆发,该业务收入从 2024 年约 7504 万元人民币大增近三倍至 2025 年的 2.96 亿元,形成手机 + 次世代显示双引擎增长格局。硬核研发与品牌信赖筑牢护城河全球显示驱动芯片长期由韩国、中国台湾地区厂商主导,云英谷科技凭借全栈自研技术打破格局。公司掌握显示驱动芯片设计、驱动补偿算法、像素补偿电路布局三大核心技术,围绕两大主轴开发近 20 个产品系列,核心性能达行业前列。其自研算法与电路大幅提升显示效果与模组良率,成为大陆少数具备完整算法能力的驱动芯片厂商。产品层面,公司率先推出 LTPO 驱动芯片(支持 1–120Hz 动态刷新率),亦是大陆首家实现 RAM-less AMOLED 驱动芯片品牌量产的企业,有效推动 AMOLED 向中低端手机渗透。在 Micro-OLED 领域,公司为全球首家推出超高分辨率、高发光频率驱动方案的厂商,成为高阶 VR 设备主流选择。2023 至 2025 年,公司累计研发投入达 6.85 亿元,占总收入 25.2%,研发费用复合增长 22.6%。高强度研发支撑产品结构升级,收入由 2023 年 7.20 亿元增至 2025 年 11.06 亿元。登陆国际资本舞台 开启全新成长周期本次港股上市,云英谷科技募资将用于技术研发、产品矩阵拓展与产业链整合。公司正从手机 AMOLED 驱动芯片领先者,向全品类显示驱动方案提供商升级:产品纵深上,加速布局 AMOLED TDDI(触控显示集成)芯片,目标 2027 年出货占比超五成;同时布局 Micro-LED 显示背板驱动,覆盖车载、商业显示、AR/VR 等场景。应用广度上,从手机、VR/AR 延伸至平板、车载、智能穿戴等中大尺寸领域,目前已与头部品牌展开验证,预计 2028 年前陆续贡献收入。随着 AI 终端、折叠屏、智能眼镜等新场景带动高性能显示需求爆发,凭借技术、客户与资本优势,云英谷科技不仅将持续引领国产替代,更有望成为定义下一代显示标准的核心力量。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
华讯马来西亚生产基地正式启用 优化多元产能布局 迈向新阶段业务增长 ACN Newswire

华讯马来西亚生产基地正式启用 优化多元产能布局 迈向新阶段业务增长

香港, 2026年6月5日 - (亚太商讯 via SeaPRwire.com) - 领先电子产品生产商华讯股份有限公司(「华讯」或「集团」)(股份代号:833)宣布其位于马来西亚槟城的生产基地正式启用。该新设施为集团多元制造布局策略的重要里程碑,标志着拓展中国内地以外产能,并进一步强化东南亚的生产网络。该槟城厂占地约60,000平方呎,设有12条生产线,每月产能达250,000至300,000件。该厂作为原始设备制造(OEM)生产基地,主要生产销往国际市场的工业电子产品、环境控制设备及电子电源模块。新增产能不仅扩大集团的整体制造规模,亦满足持续增长的市场需求,为未来业务拓展提供稳固基础。是次启用乃承接集团于2025年完成的多项策略性部署,包括收购位于马来西亚槟城及越南胡志明市的制造业务。进军马来西亚为集团首次在中国内地以外建立生产据点。集团于2025年8月完成收购槟城厂后,展开扩建及升级,引入先进设备及优化生产流程,以提升效率及质量管理水平。该设施现时生产灌溉传感器、恒温器、保安设备及锂电池组。华讯主席兼执行董事林贤奇先生表示:「槟城厂在推动集团建立更多元化制造网络的策略中发挥关键作用。配合越南业务的拓展,我们正持续强化生产能力,提升整体供应链的灵活性,有助进一步增强集团的韧性与应变能力,使我们能在瞬息万变的全球环境下更有效支持客户业务发展。」华讯行政总裁兼执行董事林子泰先生补充指:「槟城厂正稳步提升产能,并已承接现有及新客户的新增订单。随着生产线扩充及系统升级完成,产能将更趋充裕,以配合未来需求。集团亦正评估于马来西亚设立另一个具相若产能的生产基地,推动下一阶段的业务增长。」 马来西亚官方代表、华讯董事局成员及管理层于当地新厂房举行剪彩仪式。华讯马来西亚生产基地配备12条生产线,每月产能达250,000至300,000件,进一步扩大集团制造规模,满足持续增长的客户需求。有关华讯股份有限公司(股份代号:833)华讯股份有限公司主要从事设计及生产多款高质量且时尚的电子产品。本公司为明晟(「MSCI」)香港微型指数成份股。有关详情,请浏览网页http://www.alltronics.com.hk/。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
Alltronics Officially Opens Malaysia Facility ACN Newswire

Alltronics Officially Opens Malaysia Facility

HONG KONG, Jun 5, 2026 - (ACN Newswire via SeaPRwire.com) - Alltronics Holdings Limited (“Alltronics” or the “Group”) (SEHK: 833), a leading manufacturer of electronic products, announced the official opening of its manufacturing facility in Penang, Malaysia. The new operation marks an important milestone in the Group’s strategy to diversify its manufacturing footprint beyond the Chinese Mainland while deepening its production presence in Southeast Asia.The Penang facility spans approximately 60,000 square feet and houses 12 production lines, providing a monthly production capacity of 250,000 to 300,000 units. It operates as an OEM manufacturing base for industrial electronics, environmental control and electronics power modules, serving international customers. The additional capacity broadens the Group’s manufacturing scale, reflects growing customer demand and creates a platform for further business development.The opening builds on the Group’s strategic initiatives completed in 2025, including the acquisition of manufacturing operations in Penang, Malaysia, and Ho Chi Minh City, Vietnam. The move into Malaysia represented the Group’s first production foothold outside the Chinese Mainland. Following the acquisition in August 2025, the Group has expanded and upgraded the Penang facility with advanced equipment and process improvements to strengthen efficiency and quality control. It now manufactures irrigation sensors, thermostats, security devices and lithium battery packs.Mr. Lam Yin Kee, Chairman and Executive Director of Alltronics, said, “The Penang facility plays an important role in advancing the Group’s strategy to build a more diversified manufacturing network. Together with our expansion into Vietnam, we are reinforcing our production capabilities and increasing supply chain flexibility across our operations. These initiatives strengthen the Group’s resilience and agility in supporting our customers in an increasingly dynamic global environment.”Mr. Lam Chee Tai, Eric, Chief Executive and Executive Director of Alltronics, added, “The Penang operation is ramping up steadily and is already supporting a growing pipeline of orders from existing and new customers. With expanded production lines and upgraded systems, we are ready to scale output as demand increases. The Group is evaluating the potential establishment of another facility in Malaysia with comparable capacity to support the Group’s next phase of growth.” Official representatives of Malaysia, together with Alltronics’ Board of Directors and management, officiate at the ribbon-cutting ceremony for the Group’s new Malaysia facility. With 12 production lines and a monthly capacity of 250,000 to 300,000 units, Alltronics’ Malaysia facility broadens the Group’s manufacturing scale and supports growing customer demand.About Alltronics Holdings Limited (Stock code: 833)Alltronics Holdings Limited is mainly engaged in the design and manufacture of a wide range of electronic products with quality and style. The Company is a constituent stock of the Morgan Stanley Capital International (“MSCI”) Hong Kong Micro Cap Index. For more information, please visit the company website http://www.alltronics.com.hk/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
ERA 2026:君圣泰医药口头报告HTD1801肾脏保护最新研究结果 ACN Newswire

ERA 2026:君圣泰医药口头报告HTD1801肾脏保护最新研究结果

香港, 2026年6月5日 - (亚太商讯 via SeaPRwire.com) - 君圣泰医药(股票代码:2511.HK),一家专注于心肾代谢系统疾病(CKM)、开发多功能多靶点疗法的创新生物医药公司,今日在英国格拉斯哥举行的第63届欧洲肾脏协会(ERA)年会上,以口头报告的形式公布了其核心产品HTD1801的肾脏保护最新研究结果。HTD1801是全球首创的靶向AMPK-NLRP3通路的抗炎代谢调节剂(AIMM)。在已完成的III期临床研究(SYMPHONY-1&2)中,HTD1801显著改善了基线eGFR为60–90 mL/min/1.73m²的2型糖尿病(T2DM)患者的肾功能。治疗52周后,这些患者的eGFR平均升高了+3.08 mL/min/1.73m²(95% CI: 0.46–5.70),且未出现高滤过或体液潴留。这些结果提示,HTD1801和现有机制药物有差异化优势,并具有延缓甚至逆转疾病进程的潜力。本项研究进一步解释了上述临床结果。该研究由君圣泰医药与中国医学科学院医药生物技术研究所蒋建东院士研究团队共同完成,结果显示,在葡萄糖及棕榈酸诱导的足细胞损伤模型中,HTD1801可显著提升足细胞存活率、抑制细胞凋亡;恢复足细胞关键结构蛋白nephrin与podocin的表达;并显著降低代谢性炎症通路中磷酸化NF-κB及凋亡执行蛋白caspase-3水平。在糖尿病肾病(DN)模型中,HTD1801可呈剂量依赖性改善肾脏组织结构,降低肾小管损伤评分,减轻肾脏炎症及纤维化病变,并显著降低24小时尿微量白蛋白水平。该研究系统性阐明HTD1801可抑制足细胞炎症与凋亡、稳定肾小球结构,进一步揭示了HTD1801的肾脏保护潜力,为其成为慢性肾病(CKD)及其他肾脏疾病的潜在疗法提供了重要的科学依据。摘要标题:HTD1801减轻足细胞凋亡与肾小球损伤--肾脏保护机理探析报告编号:2243报告时间:2026年6月4日,星期四,上午8:15(英国夏令时间)报告形式:口头报告报告人:Filip Surmont博士,君圣泰医药首席医学官君圣泰医药首席医学官Filip Surmont博士表示:"此次研究首次从足细胞与肾小球层面揭示了HTD1801的肾脏保护作用。临床研究与临床前研究结果的高度一致,进一步证实了HTD1801在CKD或其他肾脏疾病中直击核心病理进程的能力,彰显了其重要治疗潜力。我们将持续推进HTD1801在CKD等适应症的临床开发,力求为全球肾病患者带来更多创新的治疗选择。"关于HTD1801HTD1801是一款全球首创的新分子实体,旨在解决心肾代谢系统疾病(CKM)的未满足临床需求。HTD1801作为单一分子,是具有独特双机制的口服抗炎及代谢调节剂(AIMM),通过激活AMPK及抑制NLRP3炎症小体发挥其生物学活性;这种互补协同的双机制作用可有效解决代谢问题。全球多项临床结果验证HTD1801具有"一药多效"的特性,能够为患者带来综合获益,包括改善胰岛素敏感性、血糖控制、血脂降低、肾脏保护、体重减轻、肝脏获益及抗炎等。基于此,HTD1801有潜力成为CKM领域的基础性治疗药物。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
ERA 2026: HighTide Therapeutics Presents New Findings Supporting HTD1801’s Renoprotective Potential in Oral Presentation ACN Newswire

ERA 2026: HighTide Therapeutics Presents New Findings Supporting HTD1801’s Renoprotective Potential in Oral Presentation

GLASGOW / HONG KONG - Jun 5, 2026 - (ACN Newswire via SeaPRwire.com) - HighTide Therapeutics, Inc. (2511.HK), an innovative biopharmaceutical company specializing in the development of multifunctional, multi-targeted therapies for cardiovascular–kidney–metabolic (CKM) diseases, today presented new findings on the renoprotective effects of its lead candidate HTD1801 in an oral presentation at the 63rd European Renal Association (ERA) Congress in Glasgow, UK.HTD1801 is a first-in-class anti-inflammatory metabolic modulator (AIMM) targeting the AMPK-NLRP3 axis. In the completed Phase III trials (SYMPHONY-1 and 2), HTD1801 demonstrated significant improvement in renal function in patients with Type 2 Diabetes Mellitus (T2DM) and baseline eGFR of 60–90 mL/min/1.73m². Treatment of these patients with HTD1801 resulted in a mean increase of +3.08 mL/min/1.73m² in eGFR after 52 weeks (95% CI: 0.46–5.70), without evidence of hyperfiltration or fluid retention. These findings suggest that HTD1801 may differentiate from existing therapies, with the potential to delay or prevent disease progression.This study was conducted by HighTide Therapeutics in collaboration with the research team led by Academician Jiandong Jiang at the Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, and further explored the mechanistic basis underlying these clinical observations. In glucose- and palmitic acid-induced podocyte injury models, HTD1801 significantly preserved podocyte viability and inhibited apoptosis. HTD1801 also restored expression of the key podocyte structural proteins nephrin and podocin, while reducing the levels of the inflammatory marker phosphorylated NF-κB and the apoptosis executioner caspase-3. In a diabetic nephropathy (DN) model, HTD1801 demonstrated dose-dependent improvements in renal architecture, reduced tubular injury scores, attenuated renal inflammatory and fibrotic changes, and drove a robust decrease in 24-hour urinary microalbumin.The study systematically demonstrated that HTD1801 suppresses podocyte inflammation and apoptosis while stabilizing glomerular structure, providing the latest findings supporting its renoprotective potential. These findings provide important scientific rationale for the development of HTD1801 as a potential disease-modifying therapy for chronic kidney disease (CKD) and other renal diseases.Abstract Title: HTD1801 Attenuates Podocyte Apoptosis and Glomerular Injury: Mechanistic Insights into RenoprotectionPresentation Number: 2243Presentation Date/Time: Thursday, June 4, 2026, 8:15 a.m. BSTFormat: Oral PresentationSpeaker: Dr Filip Surmont, Chief Medical Officer of HighTide Therapeutics"This study provides the first evidence into the renoprotective effects of HTD1801 at the podocyte and glomerular levels. The convergence of clinical and preclinical data further supports the disease-modifying potential of HTD1801 and its ability to target fundamental pathophysiologic processes in CKD or other renal diseases," said Dr Filip Surmont, Chief Medical Officer of HighTide Therapeutics. "We will continue advancing the clinical development of HTD1801 across CKD and related indications to provide more treatment options for patients worldwide."About HTD1801HTD1801 is a first-in-class new molecular entity that targets the residual risks underlying cardiovascular–kidney–metabolic (CKM) diseases. It is an orally delivered, anti-inflammatory metabolic modulator (AIMM) that, as a single molecule, exerts a unique dual mechanism of action through activation of AMP Kinase and inhibition of the NLRP3 inflammasome, two complementary pathways that mitigate metabolic dysfunction. Multiple global clinical studies have demonstrated the comprehensive benefits of HTD1801, including improved insulin sensitivity, glycemic control, lipid lowering, renal protection, weight reduction, hepatic improvement, and anti-inflammatory effects. Collectively, these findings support the potential of HTD1801 to serve as a foundational therapy in CKM disease management. For more information, please visit www.hightidetx.com Contact: pr@hightidetx.com Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
ONERHT Foundation Raises Over S$280,000 for Local Charities and Announces New Leadership at 11th Anniversary Charity Golf & Gala Dinner ACN Newswire

ONERHT Foundation Raises Over S$280,000 for Local Charities and Announces New Leadership at 11th Anniversary Charity Golf & Gala Dinner

SINGAPORE, June 5, 2026 - (ACN Newswire via SeaPRwire.com) - ONERHT Foundation Ltd (“Foundation”), the corporate social responsibility vehicle of RHTLaw Asia LLP and the RHT Group of Companies (collectively, “ONERHT”) celebrated its 11th anniversary by hosting the annual Charity Golf & Gala Dinner at Sentosa Golf Club on 28 May 2026.The event, graced by Guest of Honour Mr Masagos Zulkifli, Minister for Social and Family Development, drew over 120 golfers from Singapore’s legal and professional community for a day of sports and philanthropy, culminating in a gala dinner that reaffirmed the Foundation’s enduring commitment to make a difference in the lives of those it serves. The event also marked the 15th anniversary of RHTLaw Asia LLP.The Foundation raised more than S$280,000 through the event to benefit four local charities, namely PCF Sparkle Care, Singapore Road Safety Council, Singapore Golf Association, and Bethel Community Services.In addition to the fundraising milestone, the evening saw a leadership transition within the Foundation. Ms Kaylee Kwok stepped down as Chairman with effect from 28 May 2026, having stewarded the Foundation through 4 years of sustained growth and deepening community impact.“It has been a great privilege to serve as Chairman of ONERHT Foundation. What began as a conviction that the legal and professional community could do more has grown into something truly meaningful, with over S$6 million raised, more than 40 beneficiaries supported, and countless lives touched across Singapore and the region. I am deeply grateful to our sponsors, donors, partners and our ONERHT colleagues for their strong support and commitment. I leave with full confidence that the Foundation’s best years are still ahead,” said Ms Kaylee Kwok.Mr Nandakumar Renganathan has been appointed as the new Chairman of ONERHT Foundation, also with effect from 28 May 2026. Mr Nandakumar brings with him a deep commitment to the Foundation’s mission and vision to extend its reach across Singapore and the broader ASEAN region.“I am deeply honoured to take on this role and equally grateful to Kaylee for her leadership and contributions to the Foundation. ONERHT Foundation stands for something bigger than any one of us, a belief that those of us in the legal and professional community have a responsibility to give back, not just once, but consistently and with purpose. I look forward to working with our sponsors, donors, partners and beneficiaries as well as our ONERHT colleagues to carry that mission forward and extend our reach even further across Singapore and ASEAN,” said Mr Nandakumar.The evening also witnessed the signing of a Memorandum of Understanding (MOU) between RHTLaw Asia and the Association for Persons with Special Needs (APSN), marking a new chapter in the Foundation’s commitment to building meaningful and lasting partnerships with the communities it serves. ONERHT Foundation LtdA Singapore registered charity and grant-making philanthropic organisation, ONERHT Foundation Ltd (“Foundation”) enables RHTLaw Asia LLP and the RHT Group of Companies (collectively, “ONERHT”) to do right and do good through various charitable endeavours. Set up by ONERHT in 2015, the Foundation was registered as a Singapore charity by the Commissioner of Charities and a grant-making philanthropic organisation by the Inland Revenue Authority of Singapore on 16 September 2016 and 28 November 2016 respectively.The Foundation seeks to establish, inspire and encourage the right philanthropic culture among the corporate and legal fraternity of giving back to the community in a focused, hands-on and meaningful manner. Since its inception, the Foundation has raised more than S$6 million to support more than 40 beneficiaries involved in education, environmental protection and sustainability, disadvantaged groups as well as the arts and sports.For more information, please visit www.onerht.foundationFor media enquiries, please contact:Melody OngEmail: melody@waterbrooks.com.sg+65 8901 9780General enquiries:Email: query@waterbrooks.com.sg+65 9338 8166 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
Everest Medicines Enters Commercialization License Agreement with Mabworks for Bejescin(R) in the Asia-Pacific Market ACN Newswire

Everest Medicines Enters Commercialization License Agreement with Mabworks for Bejescin(R) in the Asia-Pacific Market

HONG KONG, Jun 4, 2026 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK) announced that it has entered into a commercialization license agreement with Beijing Mabworks Biotech Co., Ltd. (“Mabworks”), under which the Company has obtained exclusive rights for the clinical development and commercialization of Bejescin(R) (MIL62, Obinutuzumab beta Injection) across the Asia-Pacific region, including Southeast Asia, India, South Korea, Australia, New Zealand, Hong Kong SAR, Macao SAR, and Taiwan region, China. Under the terms of the agreement, Everest Medicines will pay Mabworks an upfront payment of RMB 23 million and sales milestone payments of up to RMB 186 million. Mabworks will also be eligible to receive a share of gross profit in the region.This collaboration will strengthen Everest Medicines’ presence in nephrology and autoimmune diseases across the Asia-Pacific region, creating synergies with its nephrology portfolio. Leveraging its established and proven clinical development and commercialization capabilities, the company aims to advance the development of Bejescin(R) and support its launch in the Asia-Pacific region, while furthering its long-term strategy in the global innovative medicines market.Bejescin(R) (MIL62, Obinutuzumab beta Injection) is a novel third-generation anti-CD20 monoclonal antibody. As shown in relevant sources, it was approved in China in February 2026 for the treatment of neuromyelitis optica spectrum disorder (NMOSD), becoming the first CD20 antibody approved for this indication globally and the first domestically developed therapy in China. The New Drug Application (NDA) for primary membranous nephropathy (PMN) is currently under Priority Review by the National Medical Products Administration (NMPA), with the potential to become the first approved targeted therapy for PMN worldwide. Bejescin(R) is also in Phase III trials for systemic lupus erythematosus (SLE) and follicular lymphoma (FL), with potential for further expansion into other autoimmune indications.“We are delighted to collaborate with Mabworks on Bejescin(R). As the first CD20 antibody approved globally for NMOSD, Bejescin(R) has demonstrated strong clinical potential and significant opportunities in nephrology and autoimmune diseases,” said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. “This collaboration strengthens Everest’s portfolio in these therapeutic areas and complements our existing pipeline. With our expertise in clinical development and commercialization, we are confident in advancing Bejescin(R) across the Asia-Pacific region, bringing this innovative therapy to more patients and improving access. At the same time, we are committed to further strengthening Everest Medicines’ presence in the Asia-Pacific and global innovative medicines market.”“We are thrilled to announce our partnership with Everest Medicines on Bejescin(R) across the Asia-Pacific region. As the first approved CD20-targeted therapy for NMOSD worldwide and the potential global first targeted therapy for PMN, Bejescin(R) possesses exceptional product competitiveness and market potential.” said Mr. Luning Chen, President of Mabworks. “Since its launch in Mainland China, Bejescin(R) has achieved outstanding commercial performance. This collaboration will further strengthen Bejescin(R)’s commercial network and brand influence across the Asia-Pacific region, bringing ‘New Hope’ to more patients with renal and autoimmune diseases.”Bejescin(R) has shown meaningful clinical and therapeutic benefits across nephrology and multiple autoimmune disease areas, with potential for further indication expansion. Its development in NMOSD, PMN, and SLE is expected to provide more innovative treatment options for patients.NMOSD is a debilitating autoimmune disorder targeting the central nervous system characterized by high recurrence and disability rates, predominantly affecting young and middle-aged women. The disease typically presents acute or subacute onset and can progress rapidly, with approximately 90% of patients relapsing within three years. Severe cases may result in blindness or paralysis. Bejescin(R) has demonstrated a significant reduction in relapse risk as a monotherapy, with strong efficacy data underscoring both its clinical value and the convenience.PMN is one of the most common pathological types of adult nephropathy, with approximately 30%-40% of patients progressing to end-stage renal disease (ESRD) within 5 to 15 years. Globally, there are no approved targeted therapies for PMN. Phase III clinical data demonstrated that Bejescin(R) monotherapy provides significant advantages across multiple efficacy endpoints including complete clinical remission, complete immunological remission and overall clinical remission. Furthermore, Bejescin(R) showed a favorable safety and tolerability profile, together with a convenient dosing regimen. Following initial treatment, patients require only one intravenous infusion every six months, reducing treatment burden and supporting long-term treatment adherence.SLE is a chronic, systemic autoimmune disease that primarily affects young women. For this indication, Bejescin(R) is in Phase III clinical trial and offers the potential for administration every 24 to 28 weeks, addressing the need for long-acting therapies and providing an improved treatment option for patients with SLE.This collaboration is regarded as an important strategic step for Everest Medicines to deepen its footprint in the nephrology and autoimmune disease areas. With the development and commercialization of Bejescin(R) in indications such as PMN, the company’s nephrology product portfolio will be further strengthened, enhancing the synergistic effects within its existing pipeline.In addition, there is a broad consensus in the industry that the coming years may represent an important window of opportunity for the accelerated adoption of innovative Chinese medicines into the Asia Pacific region. Chinese innovation is becoming increasingly competitive in clinical value, affordability and accessibility, with growing alignment to the needs of healthcare systems and patients across the region. In recent years, Everest Medicines has continuously advanced its regional strategy in Asia-Pacific, gradually building an integrated capability system covering clinical development, market access, and commercialization. By introducing innovative products with differentiated clinical value such as Bejescin(R), the company is further expanding its regional product portfolio and market coverage, realizing the commercial value of its nephrology and autoimmune disease businesses, and injecting new growth momentum into its Asia-Pacific operations. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
SnowValley Secures New Partnerships Across Major Global Food Exhibitions in H1 2026, Steadily Expanding Its International Business ACN Newswire

SnowValley Secures New Partnerships Across Major Global Food Exhibitions in H1 2026, Steadily Expanding Its International Business

Zhangjiakou, China, June 4, 2026 - (ACN Newswire via SeaPRwire.com) - In the first half of 2026, SnowValley, China's leading frozen potato product manufacturer, showcased its products and solutions at 4 of the world's premier food industry events — Gulfood in the Middle East, FOODEX Japan, FHA Food & Beverage in Singapore, and THAIFEX-Anuga Asia in Thailand. Through its presence at these flagship exhibitions, SnowValley further strengthened its reach across key consumer markets in the Middle East, East Asia, and Southeast Asia.Leveraging these world's top food industry exhibitions, SnowValley showcased its integrated industrial chain competitiveness and global service capabilities, attracting widespread attention from industry professionals, international buyers, and leading media worldwide.Recognized for multiple consecutive years among the Top 500 Chinese Brands and Top 500 Asian Brands, SnowValley continues to strengthen its international brand presence through its localized market strategies and deep engagement with overseas distribution networks across multiple countries. By securing a series of cross-border strategic partnerships, the company is further expanding its worldwide network and reinforcing its position in the global frozen potato products industry.Throughout the exhibitions, SnowValley earned strong recognition and trust from global buyers by leveraging its highly standardized manufacturing system, market-driven product customization capabilities, and efficient & reliable global supply chain. Today, SnowValley offers a portfolio of more than 160 SKUs, with products exported to over 40 countries and regions worldwide.With years of dedication to the potato products industry, SnowValley has achieved an all-round internationalization upgrade spanning product exports, brand development, and industry-standard promotion, driven by quality and innovation as the core and supported by global operations.Looking ahead, SnowValley will continue to enhance its product R&D capabilities and expand its international presence. By delivering high-quality deep-processed potato products, SnowValley aims to empower the development of the global foodservice industry, promote the standardization and upgrading of the sector through leading quality, and continuously explore and create sustainable value within the global food supply chain.Company: SnowValley Food Hebei Co.,Ltd.Contact Person: Joyce YangEmail: sales@snowvalleyfood.comWebsite: https://snowvalleyfood.com/en/Telephone: +86 131 6429 9552City: Zhangjiakou, Hebei Province Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More

龙丰首日上市:定价吸引 基本面扎实具关注价值

香港, 2026年6月5日 - (亚太商讯 via SeaPRwire.com) - 龙丰(2290)今日(6月5日)正式于港交所挂牌上市,成功踏入国际资本市场。公司公开发售部分获得13.4万人认购,超购超过660倍,足证龙丰受到市场欢迎。公司最终定价为5.18港元,上市后市值约25.9亿元,公司预估2026财年全年纯利约2.65亿港元,即2026年预测市盈率9.8倍,相对同业莎莎(00178)目前动态市盈率超过20倍,龙丰上市定价极具吸引力。加上,公司亦承诺上市后每年建议分派的股息将不低于可供分配溢利的50%,以上市定价计,即2026年预测息率近5厘,此举不仅彰显其成长性,同时亦为投资者提供稳定的回报预期,相信会得到投资者追捧。复合年增长率达50%,业绩增长强劲龙丰近年表现出明显的高增长特征。2023至2025财年总收入由约10.94亿港元上升至24.61亿港元,复合年增长率达50%。2026财年首八个月收入约20.35亿港元,同比增长34.7%,纯利则大幅上升85.8%至约1.48亿港元,并预估全财年纯利将达约2.65亿港元。值得关注的是,龙丰并非单纯依靠开店推动收入,而是收入与盈利同步提升,反映其经营质素持续改善。毛利率由2023财年的24.9%提升至2025财年的31.6%,显示供应链优化及产品结构升级正在转化为实际盈利,这种增长结构在零售板块中相对具吸引力。供应链优势突出,构成长期竞争壁垒龙丰的核心优势在于其对供应链的深度掌控。集团采用“全球直采+长期合作”模式,与超过600家供货商建立稳固合作关系,覆盖日本、韩国及欧美等市场。这不仅提升产品稳定性,更巩固其议价能力及货源优势。在此基础上,公司可持续优化产品结构并提升毛利率,同时配合自有品牌发展,目前已建立逾40个品牌,提供超过700款产品。供应链与品牌结合,使龙丰由单一零售渠道逐步转向具备品牌延展能力的平台型零售商,为长远发展提供支撑。“多品类+大店”模式,提升消费与盈利能力从业务模型来看,龙丰采用“大店型+多品类”策略。每间门店一般提供超过9,000个SKU,覆盖医药、保健及美妆等11大品类。该模式有助提升顾客停留时间及客单价,同时促进交叉销售,带来更高的营运效率。此外,门店布局覆盖核心旅游区与民生地区,形成“旅客消费+本地需求”的双重客源结构。这不仅可受惠旅客回流带来的增量需求,亦具备稳定消费基础,使整体业务在不同周期下仍能维持相对稳定表现。门店高效复制,扩张确定性较强龙丰的门店模型亦具备高效率特点。据招股书披露,新店平均仅需3个月内即达至收支平衡,2至8个月内回本,这反映其在选址、营运及成本控制方面具备成熟能力。对投资者而言,短回本周期意味着资本投入风险较低,亦有助加快资金周转。该高复制性模式为未来开店提供稳定基础,使其扩张策略具备较高确定性,而非单纯依赖市场环境或短期需求拉动。扩张与派息并行,兼具增长与回报属性龙丰计划自上市起未来三个财年增设18至21间新店,以扩大网络覆盖。同时,公司将持续强化供应链及系统建设,并推动数码化与线上线下融合发展,为未来收入及盈利增长提供支持。龙丰具备高增长、高盈利能力、供应链优势及清晰派息政策等多项特点,在港股零售板块中属质素较为突出的标的。同时,上市定价处于区间较低水平,反映其在吸引投资者参与和兼顾长线表现之间作出平衡。在基本面支撑下,若公司能持续兑现业绩增长及扩张策略,预期将持续吸引市场关注,具备中长线跟踪价值。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
云顶新耀与天广实达成倍捷欣(R)商业化授权许可协议 深化亚太创新药市场布局 ACN Newswire

云顶新耀与天广实达成倍捷欣(R)商业化授权许可协议 深化亚太创新药市场布局

香港, 2026年6月4日 - (亚太商讯 via SeaPRwire.com) - 云顶新耀(HKEX 1952.HK)宣布与北京天广实生物技术股份有限公司(以下简称"天广实")达成商业化授权许可合作协议,获得倍捷欣(R)(MIL62,通用名:奥妥珠单抗β注射液)在亚太地区(东南亚、印度、韩国、澳大利亚、新西兰、中国香港、中国澳门及中国台湾地区)的临床开发及商业化权益。根据相关协议,云顶新耀将向天广实支付人民币2,300万元的首付款,以及最高不超过人民币1.86亿元的销售里程碑款。天广实可获得该产品在亚太地区的销售毛利额分成款项。此次合作将进一步强化云顶新耀在肾科及自身免疫疾病等领域的亚太市场布局,并与现有肾科管线形成协同效应。云顶新耀将依托已获验证的临床开发及商业化能力,加速推动倍捷欣(R)的市场准入与商业化进程,持续释放亚太区域的增长潜力,并推进公司在全球创新药市场的长期战略发展。倍捷欣(R)是天广实自主研发的创新型第三代CD20抗体药物。根据相关资料显示,该药物已于2026年2月在中国获批上市,用于治疗视神经脊髓炎谱系疾病(NMOSD),成为全球首款治疗该疾病的CD20抗体,也是中国在该领域的首款国产药物。倍捷欣(R)用于治疗原发性膜性肾病(PMN)的新药上市申请亦处于中国国家药监局的"优先审评审批"阶段,有望成为全球首款获批的PMN特效药物。此外,倍捷欣(R)正在进行的临床III期试验覆盖系统性红斑狼疮(SLE)以及滤泡性淋巴瘤(FL)多个治疗领域,并具备向其他自身免疫性疾病持续拓展的潜力。云顶新耀董事会主席吴以芳表示:"我们非常高兴能与天广实就倍捷欣(R)达成此次合作。倍捷欣(R)不仅是全球首款获批治疗NMOSD的CD20抗体,也是一款具有差异化优势和广阔市场前景的创新药,在肾科及自身免疫疾病领域展现出显著的临床潜力。此次合作将进一步丰富云顶新耀在肾科及自身免疫领域的产品布局,并与现有管线形成良好的协同效应。依托公司已建立并持续强化的临床开发及商业化能力,我们有信心加速推进倍捷欣(R)在亚太地区的开发与商业化进程,推动其尽快惠及更多患者,让创新疗法更快转化为临床可及性,并进一步提升公司在亚太及全球创新药市场的影响力。"天广实总裁陈鲁宁表示:"我们非常欣喜与云顶新耀达成倍捷欣(R)在亚太地区的合作。倍捷欣(R)作为全球首款获批治疗NMOSD的CD20靶向药物,也是潜在全球首款治疗PMN的特效药物,拥有非常出色的产品竞争力与市场潜力。自产品上市以来,倍捷欣(R)在中国大陆地区已经取得了优异的商业化成绩,此次合作将进一步强化倍捷欣(R)在整个亚太市场的商业化网络与品牌影响力,为中国大陆以外的更多肾科及自身免疫性疾病患者带来「欣」希望。"倍捷欣(R)目前已在肾科及多个自身免疫疾病领域展现出显著的临床及治疗价值,并具备广阔的适应症拓展潜力。其在NMOSD、PMN及SLE等疾病领域的持续布局与进展,有望为患者带来更多创新治疗选择。NMOSD是一种高复发率、高致残率的中枢神经系统自身免疫性疾病,多发于青壮年女性。该病通常为急性或亚急性起病,可迅速进展,约90%的患者在三年内经历复发,严重者可导致失明甚至瘫痪。倍捷欣(R)在单药治疗中显示出降低复发风险的显著优势,并在疗效数据中展现出优异表现,凸显其作为单药疗法的临床价值与治疗便利性。PMN是成人肾病最常见的病理类型,约30%-40% 的患者在5-15年内可能进展为终末期肾病。目前全球范围内尚无获批的特效药。临床III期研究显示,倍捷欣(R)单药治疗在临床完全缓解、免疫学完全缓解及临床缓解等各项指标上均展现出显著优势。此外,倍捷欣(R)具有良好的安全性和耐受性,并且给药周期便捷,患者初始治疗后,每六个月仅需进行一次静脉注射,可显著降低治疗负担,同时有助于提升长期依从性。SLE是一种慢性系统性自身免疫疾病,倍捷欣(R)目前处于临床III期研究阶段,具有24–28周的长给药间隔优势,可满足患者对长效治疗方案的临床需求,有望为SLE患者提供更优治疗选择。此次合作被视为云顶新耀提升肾科及自身免疫领域战略纵深的重要举措。随着倍捷欣(R)在PMN等适应症上的开发与商业化推进,公司肾科产品矩阵将得到进一步补充,并强化现有管线的协同效应。此外,业内普遍认为,未来数年中国创新药加速进入亚太市场将迎来重要发展机遇。凭借临床价值、可负担性及可及性方面的综合优势,中国创新药与亚太地区日益增长的医疗需求持续契合。云顶新耀近年来持续推进亚太区域战略布局,已逐步形成覆盖临床开发、市场准入及商业化运营的能力体系。通过引入倍捷欣(R)等具备差异化临床价值的创新产品,云顶新耀正进一步拓展区域产品组合及市场覆盖,推动公司肾科及自身免疫领域商业化价值的释放,并为亚太业务发展注入新的增长动能。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
Using Personal Loans Wisely to Improve Your Money Situation in Singapore ACN Newswire

Using Personal Loans Wisely to Improve Your Money Situation in Singapore

SINGAPORE, June 4, 2026 - (ACN Newswire via SeaPRwire.com) - Managing money in a high-cost city like Singapore can feel complex, especially when multiple financial commitments run in parallel. From education expenses and medical bills to consolidating existing dues, Personal Loans in Singapore are often explored as a flexible financing option. When approached thoughtfully, they can help create breathing room in monthly cash flow and bring more structure to scattered payments. The key lies in understanding how these loans work in the local context and using them in ways that align with income patterns, interest rates, and realistic repayment timelines.Understanding how Personal Loans work in SingaporePersonal Loans in Singapore are unsecured loans, meaning they do not require collateral such as property or fixed deposits. Loan amounts can vary widely depending on income eligibility and lender criteria, subject to applicable regulatory requirements. Interest rates are often quoted as flat rates or effective interest rates (EIR), with EIRs commonly ranging between 2.65% and 3.75% per annum for salaried individuals. Understanding the difference between flat rates and EIRs, as well as how rates vary across lenders, can help borrowers estimate the actual cost of borrowing more accurately. Repayment tenures usually span from one to five years, offering flexibility to match monthly obligations with income cycles.Situations where Personal Loans may help improve cash flowPersonal Loans may be useful in specific scenarios where timing and predictability matter more than long-term borrowing. For instance, consolidating multiple high-interest payments into one structured loan can simplify finances and make monthly outflows easier to track. A consolidated single personal loan instalment per month may feel more manageable than juggling three or four smaller payments with varying due dates. Similarly, planned expenses such as professional certifications or home repairs may benefit from fixed monthly repayments rather than ad-hoc withdrawals from savings. This approach can help maintain liquidity while spreading costs over time.Using Personal Loans for Debt ConsolidationDebt consolidation is one of the more common reasons borrowers explore personal loans in Singapore, especially when dealing with credit card balances. For illustration purpose, credit cards may carry interest rates exceeding 25% per annum, which may strain monthly budgets if balances revolve. A Personal Loan with a materially lower EIR may help reduce the interest burden while providing a clear repayment end date. Over a three-year tenure, consolidating SGD 20,000 in outstanding balances may translate into more predictable instalments and less uncertainty around interest accumulation, depending on the applicable terms. This structured approach may help improve financial clarity without relying on short-term credit cycles.Practical tips to use Personal Loans thoughtfullyAlign the loan amount with a clear purposeBorrowing with a defined goal can help keep loan usage focused and intentional. Whether the aim is consolidating debt or funding a necessary expense, having a specific number in mind can prevent over-borrowing. In Singapore, lenders may offer higher limits based on income, but choosing only what is required can help keep monthly instalments comfortable. This approach may also reduce total interest paid over the loan tenure.Compare EIR, not just headline offersAdvertised rates can sometimes appear attractive, but the EIR provides a clearer picture of the total cost. Processing fees, early repayment charges, and administrative costs can influence the final amount paid. For example, a loan with a 3% flat rate can translate to an EIR closer to 5.5% once fees are factored in. Comparing EIRs across lenders can help identify options that fit better within monthly budgets.Choose a tenure that balances flexibility and affordabilityLonger tenures reduce monthly instalment amounts, but they also increase total interest paid. Shorter tenures may feel heavier on cash flow but can close the loan faster. Borrowers earning between SGD 4,000 and SGD 6,000 per month often opt for a two- to three-year tenure, as it balances instalment size with interest impact. Selecting a tenure that aligns with income stability can help maintain consistency in repayments.Understanding income-based borrowing limitsIn Singapore, borrowing limits for personal loans are typically tied to annual income levels and overall credit assessment. Individuals earning less than SGD 20,000 annually are generally subject to more restrictive unsecured credit caps, while those earning above SGD 30,000 may be eligible for higher unsecured credit limits, subject to the banks' internal credit assessments and applicable regulatory requirements. These guidelines are designed to encourage responsible borrowing without overextending financial capacity. Staying within these limits can help ensure that loan repayments remain proportionate to income, leaving room for savings and everyday expenses. This balance can support longer-term financial resilience rather than short-term relief.Building a healthier money outlook with structured repaymentsOne often overlooked benefit of personal loans is the predictability they bring to monthly planning. Fixed instalments can make it easier to map expenses, set aside savings, and track progress over time. Seeing a loan balance reduce each month steadily may also encourage better financial habits. In Singapore's fast-paced environment, this structure may help individuals stay focused on broader money goals while managing immediate needs. Over time, this clarity may contribute to improved confidence in handling finances.Making Personal Loans work for your financial contextUsing personal loans thoughtfully in Singapore can be a practical way to bring order to complex financial situations. When loan amounts, interest rates, and tenures are aligned with income and clear objectives, they can help improve cash flow and reduce financial stress. Rather than acting as a quick fix, personal loans can serve as a structured tool that supports better financial management. With careful comparison and realistic planning, they may fit into a broader strategy aimed at stability and long-term financial well-being.Disclaimer: This content is published by iQuanti Singapore Pte Ltd, an external marketer engaged and compensated by UOB LtdContact Information:Name: Sonakshi MurzeEmail: Sonakshi.murze@iquanti.comJob Title: ManagerSOURCE: iQuanti Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases, Driving Value Conversion ACN Newswire

Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases, Driving Value Conversion

HONG KONG, Jun 4, 2026 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK) announced that it has entered into an exclusive licensing and collaboration agreement with Travere Therapeutics, Inc. (NASDAQ: TVTX) for the development and commercialization of civorebrutinib (also known as EVER001), a potential best-in-class oral, covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor in all markets outside China and certain countries in East and Southeast Asia.Under the terms of the agreement, Everest will receive an upfront payment of $112.5 million. Everest is also eligible to receive up to approximately $1.03 billion in additional cash payments tied to specified clinical development, regulatory and commercial milestones across up to five indications. Travere will also pay tiered royalties on future sales in its licensed territories, ranging from high single-digit to double-digit percentages based on annual net sales thresholds. The license agreement will become effective upon satisfaction of customary conditions, including expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.Travere Therapeutics, is a Nasdaq-listed US biopharmaceutical company (NASDAQ: TVTX) with a focus on the field of rare glomerular diseases, particularly targeting IgA nephropathy and focal segmental glomerulosclerosis (FSGS). The company is also developing therapeutic programs for rare genetic metabolic diseases, such as homocystinuria (HCU). Its core product, FILSPARI®(sparsentan) is the first and only medicine approved by the FDA for the treatment of FSGS, further strengthening the company’s leading position in the renal therapy sector.Civorebrutinib has the potential to serve as a pipeline-in-a-product across multiple immune-mediated kidney diseases. As an investigational oral, covalent reversible BTK inhibitor, civorebrutinib is designed to provide differentiated efficacy, safety and convenience for patients with rare, immune-mediated kidney disease. Driven by strong clinical development capabilities, Everest Medicines has recently achieved several key milestones in global multi-center trials, in-house R&D pipeline validation, and international licensing partnerships. Civorebrutinib has demonstrated proof of concept in a Phase 1/2 clinical trial of patients with PMN. The previously reported Phase 1/2 data demonstrated rapid and sustained reductions in anti-PLA2R autoantibodies and proteinuria, with high rates of immunologic and clinical remission and stable kidney function through 52 weeks of follow-up. EVER001 possesses therapeutic development potential in multiple immune-mediated glomerular diseases, including PMN, IgA nephropathy, MCD, FSGS, and lupus nephritis. These diseases share immune-mediated mechanisms that can lead to glomerular damage, resulting in proteinuria and impaired kidney function that may ultimately require dialysis or transplant. EVER001 is expected to offer a new treatment option for more than 10 million affected patients globally. Travere plans to investigate civorebrutinib in PMN, immune-mediated FSGS and MCD, with the potential for additional indications. “This collaboration with Travere brings together deep expertise in kidney disease development and commercialization and we look forward to advancing civorebrutinib in primary membranous nephropathy, immune-mediated FSGS, and minimal change disease, delivering transformative therapies for patients with serious kidney diseases worldwide,” said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. “As a differentiated, potential best-in-class therapy, civorebrutinib has demonstrated encouraging efficacy in primary membranous nephropathy. With its highly selective and reversible covalent mechanism of action, it is well positioned to advance in development across multiple immune-mediated kidney indications. Everest remains committed to our dual-engine strategy of business development partnerships and in-house R&D. This collaboration will accelerate the global development and potential commercialization of civorebrutinib, expanding its clinical and future commercial value in autoimmune kidney diseases and the ability to deliver more innovative treatment options to patients.”“Civorebrutinib represents a strategic and complementary addition to our rare kidney disease portfolio, with the potential to become a best-in-class therapy across multiple immune-mediated rare kidney diseases,” said Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics. “Patients living with rare kidney diseases still face significant unmet need, and we believe the progress made to date in IgAN and FSGS is only the beginning of what is possible for these communities. Travere has helped to deliver important firsts in these diseases, and we believe our expertise, infrastructure and deep commitment to the rare kidney community position us well to continue advancing innovation for patients. With proof-of-concept data in primary membranous nephropathy, a differentiated profile as an oral, reversible BTK inhibitor, and expected broad mechanistic applicability across diseases such as immune-mediated FSGS, minimal change disease and beyond, we believe civorebrutinib has the potential to meaningfully advance the treatment paradigm for rare kidney disease patients.”This cooperation between Everest Medicines and Travere Therapeutics further propels the globalization of EVER001, reflecting the continued unlocking of the value of Everest Medicines innovative drugs. Currently, Everest Medicines has established a comprehensive renal product matrix inclding Nefecon®, MT1013, and EVER001, spanning indications such as IgA nephropathy, secondary hyperparathyroidism (SHPT), and a wide range of immune-mediated kidney diseases. By continuously deepening its strategic layout in nephrology, Everest Medicines is accelerating its global footprint to provide accessible and reliable treatment solutions for more patients through innovative therapies. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
云顶新耀宣布就希布替尼(EVER001)达成独家授权许可与合作协议 加速产品价值转化 ACN Newswire

云顶新耀宣布就希布替尼(EVER001)达成独家授权许可与合作协议 加速产品价值转化

香港, 2026年6月4日 - (亚太商讯 via SeaPRwire.com) - 云顶新耀(HKEX 1952.HK)宣布与Travere Therapeutics, Inc.(NASDAQ: TVTX,以下简称"Travere Therapeutics")达成独家授权许可与合作协议。根据协议,Travere Therapeutics将获得EVER001(希布替尼,civorebrutinib)除大中华区及部分东南亚国家以外区域的独家开发及商业化权益。此次合作将加EVER001的全球临床开发与商业化进程,为全球肾病患者带来创新治疗选择。根据协议,云顶新耀将获得1.125亿美元的首付款,以及在最多五个适应症上获得高达10.3亿美元的开发、注册及商业化里程碑付款。此外,基于EVER001的未来年度净销售额,云顶新耀将获得从高个位数至双位数百分比的分级特许权使用费。该交易将在满足特定交割条件及完成必要监管程序后完成交割。本次云顶新耀的合作方Travere Therapeutics是一家在纳斯达克上市(股票代码:TVTX)的美国生物制药公司,重点布局罕见肾小球疾病领域,尤其聚焦IgA肾病和局灶节段性肾小球硬化(FSGS),并在研用于同型半胱氨酸尿症(HCU)等罕见遗传代谢疾病的治疗项目。其核心产品FILSPARI®(sparsentan)是一种口服双重内皮素受体拮抗剂及血管紧张素II AT1受体拮抗剂,已获美国FDA批准用于治疗IgA肾病及FSGS,成为全球首个且唯一获批用于FSGS治疗的药物,进一步强化其在肾病治疗领域的领先地位。EVER001是一款新一代共价可逆布鲁顿酪氨酸激酶(BTK)抑制剂,具备"一个可以开发多种适应症的药物(pipeline-in-a-product)"的开发潜力。与共价不可逆BTK抑制剂相比,EVER001作为一款潜在的同类最佳产品,在保持高活性的同时具有高选择性,避免持续抑制带来的毒副作用。近年来,云顶新耀凭借强大的临床开发能力,在全球多中心临床试验推进、自主研发管线临床验证及国际授权合作等方面取得了多项里程碑进展。在EVER001的临床开发中,云顶新耀此前公布用于治疗中国原发性膜性肾病(PMN)患者的1b/2a期临床研究数据显示,EVER001展现出快速、深度且持久的免疫学和临床缓解,停药后仍持续获益,安全性高,耐受性强。这些结果支持EVER001具有治疗以蛋白尿为特征的自身免疫性肾小球疾病的潜力。EVER001具备在多种免疫介导性肾小球疾病中的开发潜力,包括PMN、IgA肾病、微小病变性肾病(MCD)、FSGS及狼疮性肾炎等。这类疾病均与异常免疫反应引发的肾小球损伤相关,可导致蛋白尿和肾功能下降,严重时甚至可能发展至终末期肾病,需要透析或肾移植治疗。EVER001有望为全球逾1000万名相关患者提供新的治疗选择。据悉,Travere Therapeutics计划在PMN、免疫介导的FSGS及MCD等适应症中推进EVER001的临床开发,并有望进一步拓展至更多适应症领域。云顶新耀董事会主席吴以芳表示:"我们非常高兴与Travere Therapeutics达成此次合作。这一合作将加速EVER001的全球开发与商业化进程,进一步释放其在自身免疫性肾脏疾病领域的临床潜力与商业价值,为全球患者带来更多创新治疗选择。作为公司自主研发的潜在同类最佳创新药物,EVER001已在原发性膜性肾病等自身免疫性肾脏疾病治疗中展现出积极潜力。凭借其差异化作用机制,EVER001具备拓展至多种自身免疫性肾脏疾病的潜力,持续释放其临床开发潜力。公司始终坚持‘BD合作+自主研发’双轮驱动战略,持续推进战略性业务拓展与自主研发,不断完善全球研发体系建设,持续提升在全球创新药领域的综合竞争力。Travere Therapeutics在美国已有获批的肾科产品,在肾病药物开发、注册及商业化方面积累了丰富经验与成熟能力。双方将充分发挥各自优势,共同推进EVER001在原发性膜性肾病、免疫介导的局灶节段性肾小球硬化及微小病变性肾病上的全球临床开发,为全球患者带来更多突破性治疗选择。"Travere Therapeutics总裁兼首席执行官Eric Dube博士表示:"EVER001作为我们罕见肾病领域管线的重要战略性补充,具有高度协同价值,并有望成为覆盖多种免疫介导罕见肾病的同类最佳疗法。罕见肾病患者目前仍面临巨大的未满足临床需求。我们认为,在IgA肾病和FSGS领域已取得的阶段性进展,仅是这一治疗领域潜力释放的开始。Travere Therapeutics持续推动该领域的重要创新与突破,凭借在罕见肾病领域积累的深厚专业经验、成熟的研发与商业化能力,以及对患者的持续承诺,我们将不断推动创新,为患者带来更多突破性治疗选择。作为一款具有差异化优势的口服可逆BTK抑制剂,EVER001在原发性膜性肾病中已展现出令人鼓舞的概念验证数据,其作用机制可覆盖免疫介导的局灶节段性肾小球硬化、微小病变肾病等更多疾病领域。我们相信,EVER001将为罕见肾病患者带来更具重要意义的治疗突破,进一步推动该领域治疗格局的重塑。"此次云顶新耀与Travere Therapeutics的合作,进一步推动了EVER001的全球化进程,也是云顶新耀创新药价值进一步释放的体现。目前,云顶新耀已形成由耐赋康®、MT1013及EVER001组成的肾科产品矩阵,覆盖IgA肾病、继发性甲状旁腺功能亢进症(SHPT)及多种免疫介导性肾脏疾病。通过持续深化肾科领域战略布局,云顶新耀正加速全球布局,以创新疗法为更多患者提供可及、可靠的治疗方案。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
港科大与天瞳威视共建物理AI科创中心 开启「物理智能」新跨越 ACN Newswire

港科大与天瞳威视共建物理AI科创中心 开启「物理智能」新跨越

香港, 2026年6月3日 - (亚太商讯 via SeaPRwire.com) - 近日,香港科技大学(港科大)与苏州天瞳威视电子科技股份有限公司(CalmCar)正式签署战略合作协议,共同成立港科大物理AI科创中心(以下简称"科创中心")。该中心将聚焦物理 AI 全栈技术突破,面向当前AI对物理世界规律理解不足、推演能力有限、行动决策缺乏可靠支撑等核心瓶颈,构建具备理解、预测、推演与决策能力的新一代物理AI技术底座,支撑自动驾驶、机械人、智能制造等战略性产业发展,助力香港成为国家物理AI创新的重要战略支点。多维度研究方向:从芯片到应用的全栈布局科创中心围绕物理AI前沿研究方向和核心应用场景,覆盖芯片与系统、基础模型与数据、隐私保护与安全治理等,通过探索及利用世界模型构建高保真策略验证与交互推演能力,让AI能够在虚拟环境中进行推演和学习,再将能力迁移到真实世界,从而显著提升AI在复杂开放环境中的泛化性、可解释性与系统可靠性,为广泛的智能应用构建长期技术底座。中心的目标打造全球物理AI创新战略枢纽,主导领域评测基准与开源平台,培养具有国际竞争力的物理AI人才。立足香港、服务国家"AI+"战略科创中心将积极服务国家"AI+"战略,以香港为立足点、粤港澳大湾区为腹地、全球为舞台,致力于成为亚太地区物理智能研究的战略高地与国际合作枢纽。中心将构建从基础研究到产业落地的端到端研究能力,为行业提供统一的技术标准和通用工具。同时,中心将依托香港的国际化优势和大湾区完备的产业链资源,加速科技成果转化,打造世界一流的物理智能研究创新中心。顶尖学术班底,筑牢科研基石科创中心由加拿大工程院院士、欧洲科学院外籍院士、IEEE Fellow、港科大计算机科学及工程学系讲座教授郭嵩教授出任主任,牵头主持各项工作。郭嵩教授长期深耕分布式计算、边缘AI及多模态大模型领域,致力于攻克AI在真实物理环境中的泛化性与可靠性难题,曾获计算机领域最高学术成就之一的IEEE Edward J. McCluskey技术成就奖,是该领域的国际领军学者。其领衔的普适智能实验室是扎根香港十年,已在物理世界建模、具身强化学习、边缘智能系统优化等领域积累了大量原创性成果,为科创中心的技术攻关奠定了坚实的理论根基。 郭嵩教授指出:"我们首创的'物理对齐'技术,将生成式视频模型升级为可交互的世界模型,标志着AI从'看世界'迈向'动手改变世界'的新阶段。通过虚拟空间无限试错,我们为下一代自动驾驶的行为预测与安全规划提供了全新范式。"郑纬民先生在致辞中定调:物理AI将是继通用大模型之后的重要战略方向。随后,他主持了战略咨询委员会与科创中心的握手合影仪式,标志着该领域正式迈入产学研融合新阶段,寄望物理AI科创中心能够持续为国家人工智能战略贡献重要力量。科创中心特邀中国工程院资深院士、中国计算机学会第十届理事长、清华大学郑纬民教授领衔战略委员会,中国工程院外籍院士、英国皇家工程院院士、欧洲科学院院士、港科大首席副校长郭毅可教授作为中心的校方顾问,将为科创中心提供坚实支持;战略委员会其他顾问成员还包括;中国工程院外籍院士、加拿大皇家科学院院士、加拿大工程院院士、滑铁卢大学沈学民教授;加拿大皇家科学院院士、微软技术院士、微软亚洲研究院常务副院长、IEEE Fellow、ACM Fellow郭百宁博士;欧洲科学院院士、IEEE Fellow、ACM Fellow、洛桑联邦理工学院(EPFL)协理副校长David ATIENZA ALONSO教授。从感知迈向理解,驱动智能系统进化相较于依赖海量数据拟合的传统AI,物理AI更强调模型对真实世界动态规律与因果结构的理解。物理AI的发展,正推动智能系统从单纯的感知识别,向融合物理一致性的动态预测、交互推理与自主决策演进。世界模型作为实现物理AI的重要技术路径之一,通过构建环境的内部表征并进行前瞻性推演,为复杂场景中的策略学习与验证提供了仿真基础,有望增强系统在分布式场景中的泛化能力与行为可靠性。依托该物理AI科创中心,共同发起方天瞳威视将率先在智能驾驶领域应用相关技术展开实践,让智驾系统不仅能看见环境,更能理解物理因果,对交通场景的演化趋势进行想象,从而实现从感知向认知的持续演进。面向未来,科创中心将致力于与更多产业合作伙伴构建合作,在不同应用场景下实践和验证物理AI技术理念,推动世界模型的技术路径创新,促进物理AI关键技术与产业生态的持续融合发展。 揭牌仪式:政产学研领袖共同见证本次科创中心揭牌仪式汇聚政界领导、学界权威、产业领军代表与投资界精英,与港科大校方代表和天瞳威视创始团队共同出席、携手揭牌,香港特别行政区立法会(科技创新界)议员邱达根先生、广州市大湾区办常务副主任陈旭先生等重磅嘉宾亲临现场,全程见证科创中心揭幕。作为本次科创中心建设的核心战略合作方,Lion X Ventures全程深度参与中心筹备与生态搭建,依托自身产业资源、跨境布局与资本优势,为中心落地营运提供全方位支撑,筑牢长远发展根基。高规格的政产学研阵容,叠加头部投资机构的战略赋能,充分彰显科创中心起步的行业高度、资源厚度与战略价值,亦标志着以港科大物理AI技术引领、多方协同联动的创新产业生态体系,在大湾区正式启航、全新启程。 港科大-天瞳威视"物理AI科创中心"正式揭牌(从左至右依次为:HSBC香港区行政总裁伍杨玉如女士,香港特别行政区立法会(科技创新界)议员邱达根先生,港科大校董会成员、评议会主席、Madhead行政总裁曾建中先生,港科大计算机科学及工程学系主任周晓方教授,中国工程院院士、中国计算机学会前理事长、清华大学教授郑纬民教授,天瞳威视董事长兼CEO王曦先生,港科大首席副校长郭毅可教授,港科大副校长(研究及发展)郑光廷教授,港科大计算机科学及工程学系讲座教授、物理AI科创中心主任郭嵩教授,广州市大湾区办常务副主任陈旭先生,OCBC中层资本及股权投资部全球主管关昭博先生,Lion X Ventures CEO郭燕妮女士) 郑光廷校长致辞:"物理智能将是未来十年重塑人类社会的核心力量。我们选择在这个时刻全力投入这个方向,不只是为了建立一个好的研究组织,而是以我们的视角定义一个新科研领域。我相信,多年后回望今天,这将是科大历史上一个重要的时刻。"学术界、产业界、投资界多方力量汇聚一堂,充分体现了此次合作的高度与影响力。科创中心的成立不仅是校企合作的里程碑,也成为沪港两地科技交流创新的典范。「产研联盟」亮灯现场 「资本联盟」亮灯现场活动现场同时启动了"产研联盟"与"资本联盟",香港科技大学、天瞳威视以及其他头部机构共同发起了两个联盟。第一批产研伙伴包括:清华大学、微软亚洲研究院、51视界(6651.HK)、沐曦股份(688802.SH)、安谋科技、辉羲智能,本次参与的投资机构有:汇丰(0005.HK)、Lion X Ventures、龙石资本、GPTX简坤资本、德联资本、G70环球家族办公室、微木控股、达武创投,这标志着围绕物理AI的产学研用协同创新生态正式启航。产研联盟将聚焦技术攻关与场景落地,资本联盟则为领先的技术成果提供资金支持和商业化路径。在人才培养层面,双方将共建接轨国际标准的产业实训体系,由天瞳威视提供真实工程场景与产业化实训机会,推动形成从基础研究、技术开发到场景应用的完整生态链所需人才的培养体系。本次港科大物理AI科创中心的成立,将进一步在全球最前沿的物理AI领域推动香港与内地的科技交流与资源整合,联合吸引产业链上下游伙伴,打造开放共赢的物理AI产业新格局。关于香港科技大学香港科技大学(港科大)(https://www.hkust.edu.hk/)是国际知名的大学,致力推动创新教学、卓越研究及具影响力的知识转移。港科大着重为学生提供全面及跨学科的教学,于《2026年 QS 亚洲大学排名》中排行第六,《泰晤士高等教育全球年轻大学排名榜2024》中排行第三,并在《泰晤士高等教育大学影响力排名2025》中全球排第19、全港第一。港科大共有11个学科入选《2026年QS世界大学学科排名》全球50强;此外,在《泰晤士高等教育世界大学学科排名2026》中,涵盖人工智能及机器学习的「计算机科学」领域连续十年蝉联全港第一。此外,港科大在全球大学就业能力排名中,一直位处全球首30名以内,反映毕业生极具竞争力。在研究及创业创新方面,逾八成的科大研究,于香港的大学教育资助委员会最新的「2020研究评审工作」被评为「国际卓越」或「世界领先」水平。截至2026年5月,港科大成员共创立了逾1,900间至今活跃的初创公司,当中包括11间独角兽企业和22间成功退场的公司(上市集资或被并购)。关于天瞳威视苏州天瞳威视电子科技股份有限公司(CalmCar)成立于2016年,是中国领先的以软件为核心的L2-L2+级及L4级驾驶解决方案提供商。按2024年装机量计,公司位居中国第二大同时提供行车与泊车解决方案的软件核心供应商,并率先在海外市场实现L2-L2+级量产方案交付。公司专注于智能驾驶关键技术,产品涵盖行车、泊车、整合驾驶员监测系统的智能座舱解决方案,以及Robobus、Robotruck、Robotaxi及Robosweeper等L4级应用场景,已与超过30 家整车厂展开合作,其中包括2024年中国销量前十强车企中的9家。战略投资者涵盖采埃孚、上汽北美、上汽恒旭、北汽产投、中国联通、地平线、千方科技、商汤科技、Lion X Ventures、华侨银行等头部产业资本,为技术创新与全球化拓展提供坚实支撑。关于Lion X VenturesLion X Ventures是一家立足产业、深耕跨境布局的专业风险投资机构,聚焦东南亚数字经济与高端制造赛道,紧抓中国企业出海东南亚的核心趋势,为高潜力早期及成长阶段企业提供资本、产业资源与全球化落地支持。Lion X Ventures隶属的狮城资本成立于2019年,是专注成长型创新企业的价值型投资机构,亦是数字经济与产业生态联合投资的实践者。机构长期聚焦新一代信息科技、产业数字化、消费科技、先进制造,同时积极布局绿色科技与碳中和赛道。依托东南亚顶级金融集团资源,采用产业龙头联合管理基金模式开展投资,以深度产业视角赋能被投企业,构建中国—东南亚双向联动的产业生态,实现资本、产业与区域发展的多方共赢。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
HKUST and CalmCar Establish the Physical AI Innovation Center, Ushering in a New Era of Physical Intelligence ACN Newswire

HKUST and CalmCar Establish the Physical AI Innovation Center, Ushering in a New Era of Physical Intelligence

HONG KONG, Jun 3, 2026 - (ACN Newswire via SeaPRwire.com) - The Hong Kong University of Science and Technology (HKUST) and Suzhou Calmcar Electronics Technology Co., Limited (CalmCar) yesterday officially signed a strategic agreement to jointly establish the Physical AI Innovation Center. The Center is dedicated to advancing full-stack physical AI technologies, addressing fundamental bottlenecks in current AI, including an insufficient understanding of the laws of the physical world, limited reasoning capabilities, and a lack of reliable support for action and decision-making.The Center will build a new-generation physical AI technology foundation capable of understanding, predicting, reasoning, and decision-making, supporting strategic industries such as autonomous driving, robotics, and smart manufacturing, while helping position Hong Kong as a key strategic hub for national physical AI innovation.Multidimensional Research Directions: Full-Stack Layout from Chips to ApplicationsThe Center will pursue research covering chips and systems, foundational models and data, privacy protection and safety governance, as well as core application scenarios. By exploring and leveraging world models to build high-fidelity strategy validation and interactive reasoning capabilities, the Center aims to train AI in virtual environments before transferring capabilities to the real world-significantly improving AI‘s generalizability, interpretability, and reliability in complex and open environments, and building a long-term technical foundation for a wide range of intelligent applications.The Center’s ambition is to become a global strategic hub for physical AI innovation, leading the development of industry benchmarks and open-source platforms, and cultivating internationally competitive talent in physical AI.Based in Hong Kong, Serving the National “AI+” StrategyThe Center will actively serve the national “AI+” strategy, positioning itself with Hong Kong as its base, the Greater Bay Area as its hinterland, and the world as its stage. It strives to become a strategic highland for physical AI research in the Asia-Pacific region and an international hub for collaboration. The Center will establish end-to-end capabilities from fundamental research to industrial deployment, providing unified technical standards and common tools for the industry. Leveraging Hong Kong’s global connectivity and the Greater Bay Area’s comprehensive industrial supply chain, the Center will accelerate technology transfer and build a world-leading research and innovation center for physical intelligence.World-Class Academic LeadershipThe Center is led by Prof. GUO Song – Fellow of the Canadian Academy of Engineering, Foreign Member of the European Academy of Sciences (EU), IEEE Fellow, and Chair Professor in the Department of Computer Science and Engineering at HKUST – who serves as its director. Prof. Guo has long been engaged in distributed computing, edge AI, and multi-modal foundation models, dedicated to solving the challenges of generalization and reliability of AI in real-world physical environments.He is a recipient of the IEEE Edward J. McCluskey Technical Achievement Award, one of the highest honors in computer engineering, and is widely recognized as an international leader in the field. He also leads the Pervasive Intelligence Laboratory (PeiLAB), which has been based in Hong Kong for a decade and has produced substantial original achievements in physical world modeling, embodied reinforcement learning, and edge intelligent systems, providing a solid theoretical foundation for the Center’s research endeavors. Prof. Guo Song remarked: “Our pioneering ‘Physical Alignment’ technology upgrades generative video models into interactive world models, marking a shift in AI from ‘seeing the world’ to ‘acting on the world.’ By enabling infinite trial and error in virtual spaces, we provide a new paradigm for behavior prediction and safety planning in next-generation autonomous driving.” Prof. Zheng Weimin stated that physical AI will be a major strategic direction following general-purpose foundation models. He then presided over the handshake and group photo ceremony between the Strategic Advisory Committee and the Innovation Center, marking the field’s official entry into a new phase of industry-academia-research integration. He expressed hope that the Center will continue to make significant contribution to the national AI strategy.The Center has invited Prof. ZHENG Weimin—Senior Member of the Chinese Academy of Engineering, 10th President of the China Computer Federation (CCF), and Professor at Tsinghua University—to chair its Strategic Committee. Prof. GUO Yike—Foreign Member of the Chinese Academy of Engineering, Fellow of the Royal Academy of Engineering (UK) and the European Academy of Sciences (EU), and Provost of HKUST—serves as the University Advisor to the Center, providing strong support.Other Strategic Committee advisors include Prof. Xuemin (Sherman) SHEN—Foreign Member of the Chinese Academy of Engineering, Fellow of the Royal Society of Canada, Fellow of the Canadian Academy of Engineering, and Professor at the University of Waterloo; Dr. Bai-ning GUO—Fellow of the Royal Society of Canada, Microsoft Technical Fellow, Managing Deputy Director of Microsoft Research Asia, IEEE Fellow, and ACM Fellow; and Prof. David Atienza ALONSO — Fellow of the European Academy of Sciences, IEEE Fellow, ACM Fellow, Professor of Electrical and Computer Engineering at EPFL, and Associate Vice President for Centers and Platforms at EPFL.From Perception to Understanding: Driving the Evolution of Intelligent SystemsUnlike traditional AI that relies on massive data fitting, physical AI emphasizes a model’s ability to understand dynamic real-world laws and causal structures. Physical AI is driving intelligent systems beyond perception and recognition toward dynamic prediction, interactive reasoning, and autonomous decision-making grounded in physical consistency. As a key enabling technology, world models simulate and anticipate environmental dynamics, providing a foundation for policy learning and validation in complex scenarios while enhancing generalization and reliability in distributed settings.Leveraging the Physical AI Innovation Center, CalmCar—as a co-founder of the Center— will take the lead in applying these technologies to autonomous driving, enabling vehicles not only to perceive their surroundings but also to understand physical causality and anticipate the evolution of traffic scenarios, thereby advancing from perception to cognition.Looking ahead, the Center is committed to building partnerships with a broader range of industry partners, validating and refining physical AI technologies across diverse application scenarios, driving innovation in world model methodologies, and fostering the sustainable integration of physical AI technologies with the industrial ecosystem.Unveiling Ceremony: Witnessed by Leaders from Government, Academia, and IndustryThe unveiling ceremony brought together government leaders, leading academics, industry executives, and investment professionals. Representatives from HKUST and CalmCar’s founding team jointly unveiled the Center. Distinguished guests, including Mr. Duncan CHIU, Legislative Council Member (Technology & Innovation) of Hong Kong, and Mr. CHEN Xu, Executive Deputy Director of the Guangzhou Greater Bay Area Office, witnessed the launch of the initiative.As a core strategic partner in establishing the Center, Lion X Ventures has been deeply involved in its preparation and ecosystem building throughout the process. Leveraging its industry resources, cross-border reach, and capital expertise, Lion X Ventures provides comprehensive support for the Center’s operations and development, laying a solid foundation for its long-term growth.The high-caliber presence of leaders from government, academia, industry, and investment community, combined with the strategic support of top investment institutions, fully demonstrates the Center’s industry standing, resource depth, and strategic value. It also marks the official launch of a collaborative innovation ecosystem in the Greater Bay Area led by HKUST’s physical AI technologies. The HKUST-CalmCar Physical AI Innovation Center inauguration ceremony(From left to right: Ms. Diana WU, CEO of HSBC Hong Kong; Mr. Duncan CHIU, Legislative Council Member (Technology & Innovation) of Hong Kong; Mr. Terry TSANG, HKUST Court Member and Chairman of the Convocation, CEO of Madhead; Prof. ZHOU Xiaofang, Head of the Department of Computer Science and Engineering at HKUST; Prof. ZHENG Weimin, Academician of the Chinese Academy of Engineering, former Chairman of the China Computer Federation, Professor at Tsinghua University; Mr. WANG Xi, Chairman and CEO of CalmCar; Prof. Guo Yike, Provost of HKUST; Prof. Tim CHENG, Vice-President for Research and Development of HKUST; Prof. Guo Song, Chair Professor of the Department of Computer Science and Engineering at HKUST and Director of the Physical AI Innovation Center; Mr. CHEN Xu, Executive Deputy Director of the Guangzhou Greater Bay Area Office; Mr. Daniel KWAN, Global Head of Mid-Capital and Equity Investment at OCBC; Ms. GUO Yanni, CEO of Lion X Ventures) Prof. Tim Cheng stated: “Physical intelligence will be a core force reshaping human society over the next decade. We have chosen this moment to fully commit to this direction—not merely to build a strong research organization, but to define a new research field from our own perspective. I believe that, years from now, when we look back on today, this will be remembered as an important moment in HKUST’s history.”The gathering of leaders from academia, industry, and investment underscores the significance and impact of this collaboration. The establishment of the Center is not only a milestone in university-industry collaboration but also a model for technology exchange and innovation between Shanghai and Hong Kong. The launch ceremony of the Industry-Research Alliance The launch ceremony of the Capital AllianceThe ceremony also marked the launch of the Industry-Research Alliance and the Capital Alliance, jointly initiated by HKUST, CalmCar, and other leading institutions. The inaugural industry partners include Tsinghua University, Microsoft Research Asia, 51WORLD (6651.HK), MetaX Integrated Circuits (688802.SH), Arm China, and Huixi Technology. Participating investment institutions include HSBC (0005.HK), Lion X Ventures, Dragonstone Capital, GPTX Investment, Delian Capital, G70 MFO, WeMove Capital, and Great Filter Venture.This marks the official launch of a collaborative innovation ecosystem spanning industry, academia, research, and application in the field of physical AI.The Industry-Research Alliance will focus on technology breakthroughs and scenario deployment, while the Capital Alliance will provide funding and commercialization pathways for leading technologies. In terms of talent development, both sides will build an industrial training system aligned with international standards, with CalmCar providing real-world engineering scenarios and hands-on opportunities, thereby nurturing a talent pipeline that spans basic research, technology development, and application deployment.The establishment of the Physical AI Innovation Center will further promote technology exchange and resource integration between Hong Kong and the Chinese Mainland in the most advanced frontier of physical AI. It aims to attract partners across the entire industrial chain and create an open, win-win ecosystem for the physical AI industry.About The Hong Kong University of Science and TechnologyThe Hong Kong University of Science and Technology (HKUST) (https://www.hkust.edu.hk/) is a world-class university known for its innovative education, research excellence, and impactful knowledge transfer. With a holistic and interdisciplinary pedagogy approach, HKUST was ranked 6th in the QS Asia University Rankings 2026, 3rd in the Times Higher Education’s Young University Rankings 2024, and 19th globally and 1st in Hong Kong in the Times Higher Education’s Impact Rankings 2025. Eleven HKUST subjects were ranked among the world’s top 50 in the QS World University Rankings by Subject 2026. In addition, in the Times Higher Education World University Rankings by Subject 2026, HKUST’s Computer Science discipline which encompasses areas such as artificial intelligence and machine learning, has been ranked No. 1 in Hong Kong for ten consecutive years. Our graduates are highly competitive, consistently ranking among the world’s top 30 most sought-after employees. In terms of research and entrepreneurship, over 80% of our work was rated “internationally excellent” or “world leading” in the Research Assessment Exercise 2020 of the Hong Kong’s University Grants Committee. As of May 2026, HKUST members have founded over 1,900 active start-ups, including 11 Unicorns and 22 exits (IPO or M&A).About CalmCarSuzhou Calmcar Electronics Technology Co., Limited (CalmCar) was founded in 2016 and is a leading software-focused provider of L2-L2+ and L4 driving solutions in China. By 2024 installation volume, it ranks as the country’s second largest software-focused provider that offers both driving and parking solutions, and the first Chinese provider to deliver mass-production L2-L2+ solutions overseas. The company focuses on key autonomous driving technologies, offering driving, parking, and intelligent cockpit solutions with integrated driver monitoring systems (DMS), as well as L4 applications including robobuses, robotrucks, robotaxis, and robosweepers. CalmCar has partnered with over 30 vehicle manufacturers, including nine of China’s top ten automakers by sales in 2024. Its strategic investors include ZF, SAIC North America, SAIC Hengxu, BAIC Capital, China Unicom, Horizon Robotics, China TransInfo, SenseTime, Lion X Ventures, OCBC, and other leading industry players, providing solid support for innovation and global expansion.About Lion X VenturesLion X Ventures is a professional venture capital institution rooted in industry and focused on cross-border investment. It targets Southeast Asia’s digital economy and high-end manufacturing sectors. Riding on the trend of Chinese enterprises expanding into Southeast Asia, we deliver capital support, industrial resources and global landing solutions for high-potential startups and growth-stage companies.Founded in 2019, Lion Partners is the parent entity of Lion X Ventures. As a value investor dedicated to growth-oriented innovative enterprises, it is also a pioneer in joint investment across the digital economy and industrial ecosystem. We maintain a long-term focus on next-generation information technology, industrial digitalization, consumer tech and advanced manufacturing, while actively expanding our footprint in green technology and carbon neutrality.Backed by resources from leading financial groups in Southeast Asia, we adopt a co-management fund model partnered with industry leaders. With profound industrial insights, we empower portfolio companies and build a two-way interactive industrial ecosystem connecting China and Southeast Asia, ultimately achieving win-win outcomes for capital, industries and regional development. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More